17th Annual International AASD Conference 2021

Arabic Association for the Study of Diabetes and Metabolism

Member of

International Diabetes Federation (IDF)

26, 27, 28 and 29
October 2021

Hybrid Event
Intercontinental Cairo Semiramis



Conference is accredited with: 19 CPD / CME Credit Hours by:
Continuing Professional Development (CPD – CME)
According to the CPD Standards of Compulsory Egyptian Medical Training Authority (CEMTA)
Accreditation Numbers: 202110010131

AASD 2021

17th International Conference

of

Arabic Association for the Study of Diabetes and Metabolism

الجمعية العربية لدراسة أمراض السكر والميتابوليزم

MEMBER OF

INTERNATIONAL DIABETES FEDERATION, IDF

26 – 29 OCTOBER, 2021

InterContinental Cairo Semiramis, CAIRO, EGYPT

HYBRID MEETING

Guest of Honor
Prof. Andrew JM Boulton
IDF President

AASD & Conference Honorary President
Prof. Raafat Rashwan

AASD & Conference President
Prof. Inass Shaltout

AASD & Conference Vice-President
Prof. Amr Abdel Wahab

Conference Vice-President
Prof. Mohamed Hassanein


Conference is accredited with: 19 CPD / CME Credit Hours by:
Continuing Professional Development (CPD – CME)
According to the CPD Standards of Compulsory Egyptian Medical Training Authority (CEMTA)
Accreditation Numbers: 202110010131

SCIENTIFIC COMMITTEE CHAIRMEN *(alphabetically)*



Prof. Amr El Meligy

Head of Internal Medicine Department
Faculty of Medicine, Cairo University



Prof. Atef Elbahry



Prof. Farid Fawzy



Prof. Hala Kahla



Dr. Mazen Attia



Prof. Mohamed-Naguib Wifi



Prof. Shereen Abdelghaffar




Prof. Yasser Abdel Hamid



Dr. Hisham Habib

Conference Moderator



Dr. Sayed Gad

AASD Treasure

AASD 2021 Guest of Honor




Prof. Andrew JM Boulton

IDF President



Prof. Raafat Rashwan

AASD & Conference Honorary President



Prof. Inass Shaltout

AASD & Conference President



Prof. Amr Abdel Wahab

AASD & Conference Vice-President



Prof. Mohamed Hassanein


Conference Vice-President

CONFERENCE BOARD *(alphabetically)*



Prof. Abdel Khalek Hamed

Conference & AASD Secretary



Prof. Hazem Ashmawy



Prof. Omar El-Saadany

In collaboration with

THE EGYPTIAN SOCIETY OF CARDIOLOGY

EGYPTIAN SOCIETY OF CARDIOLOGY

EGYPTIAN ASSOCIATION OF VASCULAR BIOLOGY AND ATHEROSCLEROSIS

EAVA



WELCOME

Dear professors and colleagues,

It gives us a great pleasure to welcome you in 17th annual virtual AASD conference.

On behalf of AASD board and members, we appreciate the strong participation and support of International Diabetes Federation, IDF. AASD as a member of IDF puts a great responsibility on all AASD members to do extra efforts for the cause of Diabetes. Let me express our gratitude to Prof. Andrew Boulton, president of the International Diabetes Federation and guest of honor of AASD conference 2020 for his extraordinary support of all AASD activities.

Due to Covid 19 pandemic, AASD has decided to host its 16th annual international conference as a virtual one, and we wish to see you all, dear faculty and attendees in AASD 2021 life events.

We appreciate the presence of our eminent guest speakers from United Kingdom, Norway, Italy, Ukraine, Russia, USA, Croatia, Macedonia, UAE, Morocco, Denmark, Portugal, Albania, Bosnia, Lebanon, Turkey, Syria, Jordan, Pakistan , Bahrain and India for their presence to share in this outstanding scientific event. Their participation added a great scientific value to the conference.

On behalf of my colleagues, board and members of AASD, let me express my gratitude to all Egyptian professors & speakers who agreed to join us and Co- chair the Advisory board and National Faculty in this virtual scientific event.

AASD as one of the leading Diabetes Associations has been recognized in December 2017 as an IDF center of education and our continuous scientific and patient activities aim to share in:

1. Public awareness and patient education with the aim of prevention and optimum management.
2. Medical conferences intending to share knowledge and stimulate research.
3. Post graduate continuous medical education (AASD-CME).
4. Newsletters for health care professionals that intend to increase knowledge about the standards of medical care in diabetes and associated co-morbidities and complications.
5. Building the capacity of thousands of doctors, nurses and educating Patients which enhanced their knowledge to cope with diabetes.

Looking forward to seeing you in 2021 life conference, In Shaalah
AASD & Conference President
Prof. Inass Shaltout

AASD Annual Conferences



AASD National Conferences: More than 31 conferences till now

AASD POSTGRADUATE COURSE:

- AASD / EASD postgraduate course 16 – 18 November, 2017
- AASD / EASD postgraduate course 12 – 14 April, 2020

AASD DIABETES CO-MORBIDITIES AND FASTING CONFERENCES:

- 1st Annual Conference, June 2012 2nd Annual Conference, June 2013
- 3rd Annual Conference, May 2014 4th Annual Conference, May 2015
- 5th Annual Conference, April 2016 6th Annual Conference, April 2017

AASD HAS THE FOLLOWING STUDY GROUPS:

- Nephrodiab Study Group
- Diabetes in the Young Study Group
- Diabetes, Obesity and Nutrition Study Group
- Rheumadiab Study Group
- Diabetes Psychological Disorders Study Group
- Diabetes and Liver Study Group

AASD CONTACT:

- www.aasdonline.com / aasd.sec@gmail.com
- Mobile: 01007930925 - 01119884994 - 01222341484
- youtube.com/AASDDiabetes
- https://www.facebook.com/AASD. https://www.linkedin.com/in/aasddiabetes
- Official/https://www.facebook.com/groups/aasd.diabetes/?ref=share
- https://t.me/joinchat/8PkXjLGL0Vg0YWQ0

EASD E-LEARNING:

https://www.easd.org/education/easd-e-learning.html

AASD EXECUTIVE COMMITTEE

Dr. **Mohamed Oraby**
Mr. **Gamal Badry**
Mr. **Ahmed Ibrahim**
Mrs. **Raneem Shurbaji**

انشطة الجمعية
AASD 2021








EASD


AASD






INTERNATIONAL
FACULTY



Prof. Andrew James Michael BOULTON (UK)

- President, International Diabetes Federation
- Professor of Medicine, University of Manchester
- Consultant Physician, Manchester Royal Infirmary.
- President, Worldwide Initiative for Diabetes Education
- Voluntary Professor of Medicine, University of Miami,
- Editor of Diabetic Medicine, Journal of the British Diabetic Association
- Senior Medical Registrar, Royal Hallamshire and Northern General Hospitals
- 2008 - 2011 Vice-President, EASD.
- 2011 - 2015 President, EASD and EFSD.
- 2015 - 2020 President, Worldwide Initiative for Diabetes Education
- 2017 to Present Chairman, EURADIA
- 2019 - 2021 President, International Diabetes Federation
- 2019 - 2021 President, International Diabetes Federation



Prof. Akhtar Hussain (NORWAY)

- President Elect of International Diabetes Federation
- Professor at the NORD University (Chronic Diseases – Diabetes)
- Guest Professor of Medicine at the Federal University of Ceara (FAMED-UFC), Fortaleza-Ceara, Brazil
- Co-chair and Professor at the Centre for Global Health, Bangladesh Diabetes Association/Bangladesh University of Health Sciences.
- Professor at the Faculty of Medicine, Institute of Health and Society, Department of International Health,
- President of the Diabetes Asian Study Group
- Executive Member of the Medical Advisor Board of the Norwegian Diabetes Association
- Co-Editor of the Journal of Diabetology



Prof. Andrew J. Behnke, MD, Face (USA)

- Assistant Professor of Internal Medicine
- Liberty University College of Osteopathic Medicine Education
- MD, Pennsylvania State University School of Medicine
- BS, State University of New York at Buffalo Course Taught
- Internal Medicine· Endocrinology - ENDO
- Professional Memberships
- Lynchburg Academy of Medicine · Medical Society of Virginia American Diabetes Association Publications
- Dietary Differences in Virginia Counties with Different Diabetes Rates" VCOM Research Meeting, 2019
- Population Differences in Diabetes in the Republic of Moldova" ADA Poster 2009
- ·Effect of BNP on the Treatment of Type 2 Diabetic Patients Receiving TZD Treatment" AACE poster, Annual Meeting 2007
- ·A Novel Education Approach in Type 1 Diabetic Patients Receiving Insulin Pump Therapy" AACE Poster 2007
- ·Population Differences in Diabetes in the Republic of Moldova" ADA Poster 2009
- ·Effects of Breast Feeding on Glucose Levels and Hypoglycemia. Results of Continuous Monitoring" ADA Poster 2004
- Do C- Peptide Levels Make a Difference in the Treatment of Type 2 Diabetes?" SAFP Poster and Oral Presentation 1992



Prof. Banshi Saboo (MD, Ph.D.) (India)

- Chief Diabetologist & Chairman of Diabetes Care & Hormone Clinic at Ahmedabad
- Honored with Fellowship of American College of Endocrinology (USA), American College of Physician (USA), International College of Nutrition (FICN), Royal College of Physicians (Glasgow), (Edinburgh), (London), MNAMS (Diabetology)
- President of RSSDI (Research Society for Study of Diabetes in India) 2019-2020
- President of AIAARO (INDIAN OBESITY SOCITEY) 2016-2020
- Hon. Vice-President of Diabetes in Asia Study Group (DASG)
- Hon. Secretary of Diabetes India
- Launched a Project "Diabetes Free India – 2030", Acknowledged by Hon'ble President of India Shri Pranab Mukherjee
- Founder of NGO, Diabetes Care India and India Sweet Registry Project Managing Editor for Sadikot's International Textbook of Diabetes
- Advisory Board Member JAPI, Journal of Diabetology, JOMR
- Expert of RSSDI Guidelines for Management of Diabetes, ATTD CGM Guidelines & ISPAD Guidelines for Pediatric Diabetes
- He has more than 50 Publications in Indexed Journals and have Contributed Chapters in Various Textbooks and Monograms
- He has Awarded Most Impactful Healthcare Leaders by World Health and Wellness Congress and Awards
- Completed Many Public Awareness Projects under Diabetes Care India, such as;
- KADAM (Knowledge based Diabetes Awareness Movement)
- IDEA (Intensive Diabetes Education & Awareness) to STOP Heart Attack
- Multiple Diabetes Clinic along with AMC with support of WDF
- Improve Standard of Care for Type 1 Diabetes in Gujarat (Supported by WDF)
-



Prof. Dario Rahelic (Croatia)

- Dario Rahelic is Assistant Professor and Head of Department of Endocrinology, Diabetes and Metabolic Disorders at Dubrava University Hospital, Zagreb, Croatia, and is President of the Croatian Society for Diabetes and Metabolic Disorders of the Croatian Medical Association. He also Serves as Executive Committee Member of the Diabetes and Nutrition Study Group of EASD, the Croatian Endocrine Society, the Croatian Society for Obesity and the Croatian Society for Endocrine Oncology.
- His Teaching Engagements are at the Faculty of Medicine, the Faculty of Food Technology and Biotechnology and the Faculty of Pharmacy and Biochemistry. He was Visiting Scientist at St. Michael's Hospital in Toronto (Canada), Mayo Clinic in Rochester (USA) and Motol Clinic, Prague (Czech Republic).



Prof. Evgenia Patrakeeva (Russia)

- Dr. Evgenia Patrakeeva is a Teaching Assistant in Endocrinology and Consultant Endocrinologist at the First St. Petersburg Medical University Names After I.P. Pavlov where She Also Received her Medical Degree in 2005, Graduating Cum Laude and Completing her Residency in Endocrinology and Internal Medicine. Her Research Interests Include Insulin Therapy, Patient Education, Psychological Issues in Diabetes Care and the Use of New Technologies in Diabetes. She also has an Interest in the Development of Web-Based Resources and Social Media use as Components of Diabetes Therapy and Patients' Psychological Support .Dr. Patrakeeva is a Member of the Advisory Board of the Education Site for Russian Diabetologists, www.diaeuni.ru, Co-Founder of the Educational Web-Resource www.rule15s.com and Educational Social Networks for Russian Speaking Diabetes Patients, @diabet.connect. She Organizes, on a Regular Basis, Postgraduate Courses for Young Diabetologists in St. Petersburg as well as an Innovative Course for CSII and Ready-for-CSII Young Patients.




Prof. Frans Pouwer (Denmark)

- Frans Pouwer is Professor of Medical Psychology, he is Affiliated to the South Danish University in Odense, Denmark. His Work is Primarily Focused on Clinically Relevant Topics, Such as Diabetes-Specific Emotional Distress, Stress in General, Depression, Diabetes Self-Care, Fear of Hypoglycemia, and Appraisals of Insulin Therapy. Frans Pouwer is Past Chair of the Psychosocial Aspects of Diabetes (PSAD) Study Group of the EASD an Also Past Chair of the European Depression in Diabetes (EDID) Research Consortium.



Prof. George Thompson (UK)

- Associate Medical Director and Director of Medical Education,
- Sherwood Forest Hospitals NHS Foundation Trust.
- Assistant Dean (International) and Regional Advisor (Trent),
- Royal College of Physicians of Edinburgh, Diabetes Editor,
- International Journal of Clinical Practice, Editorial.
- Board Member Practical Diabetes International. Clinical Director of Medicine (2001-2004), Chairman of the Hospital Medical Staff Committee (2006-2008).



Prof. Iryna Vlasenko (Ukrania)

PhD Pharmacy, Associate Professor

Vice-President International Diabetes Federation (2019-2021)

- Member of the European Medicine Agency (EMA) Working Party with Patients and Consumers.
- Health Technology Assessment EU Network.
- Member of the Ukrainian Ministry of Health's Working Group for the Development and Support of Activities for the Prevention of T2 Diabetes (2018).
- Board Member IDF- Europe (2015-2019)
- Associate Professor at the National Medical Academy of Post-Graduate Education (Ukraine) (2006-2019).
- Associate Professor at the International European University (Ukraine) (from 2020



Prof. Loretta Vileikytel (UK)

Senior Lecturer in Medicine, University of Manchester, Manchester, UK.
Voluntary Research Associate Professor, University of Miami, School of Medicine, Miami, FL, USA.

A. Personal Statement

have Been Active in Clinical Research of Diabetic Foot Complications for Over 25 Years, Focusing on the Interplay between the Biomedical and Psychosocial/ Behavioral Aspects of Diabetic Neuropathy and its Late Sequelae- Foot Ulceration. In Collaboration with my Psychology and Diabetic Neuropathy Colleagues from UK and USA (Johns Hopkins, Rutgers and Penn State Universities, Albert Einstein College of Medicine, and the University of Miami, Where I've been a Visiting Faculty Member Since 2002) I've Designed and Led Several Large Scale Multicenter/Multidisciplinary Transatlantic Research Projects. Specifically, We Developed a Neuropathy and Foot Ulcer-Specific Quality of Life Instrument (Neuroqol), Which is Being Used in Several Studies, such as the EDIC (the DCCT follow-up). I have Previously Held the First Joint American And British Diabetes Association Grant to Develop an Instrument for Assessment of Patient Cognitive/ Emotional Representations of Neuropathy as a Risk Factor Shaping Foot Self-Care. Furthermore, I Led a Collaborative (Manchester/Miami) NIH Study that Investigated the Effects of Psychological Stress on Diabetic Foot Ulcer Healing, Which Generated One of the Largest Foot Ulcer Tissue Biomarker Databases and Provided Preliminary Data for Yet Another Successful NIH Grant Application Examining the Cortisol Synthesis Enzyme, CYP11B1, as Tissue Biomarker for Diabetic Foot Ulcer Healing. In Summary, My Unique Combination of Skills and Expertise Allows Me to Study the Biological and Psychosocial/Behavioral Risk Factors of Neuropathy/Foot Ulceration in Diabetes in an Integrated Fashion, Thereby Producing Clinically Meaningful Results.



Prof. Luis Manuel Ramos Gardete, (Correia)

Graduated in Medicine and Surgery at the Faculty of Medicine of Lisbon University in 1969

- Specialized in Endocrinology, Diabetes and Nutrition in Portuguese College of Physicians in 1982.
- Senior Lecturer in Endocrinology of the Lisbon Civil Hospitals since 1991.
- Specialist in Endocrinology at APDP – Portuguese Diabetes Association since 1979.
- From 1980 Onwards, Involved in a Courses on Diabetes Prevention and Control of the Portuguese Diabetes Association, for Doctors and Nurses.
- Vice-President of the Portuguese Society of Endocrinology, Diabetes and Metabolism from 1997 to 2000.
- Clinical Director of the APDP – Portuguese Diabetes Association from 1996 to 2002.
- President of the Portuguese Society of Diabetology from 2005 to 2007.
- President of the APDP – Portuguese Diabetes Association from 2008 to 2017.
- Coordinator of the 1st Portuguese Diabetes Prevalence Study – PREVADIAB (2009).
- Chairman of the Local Organizing Committee of the EASD Annual Meetings in 2011 and 2017, in Lisbon




Prof. M. Zaman Shaikh (Pakistan)

M.B.B.S., F.C.P.S, M.R.C.P. (UK), F.R.C.P., MSc (Diabetes & Endocrinology) Glasgow University.

Director, Sir Syed Institute of Diabetes & Endocrinology (Sside),

Professor of Medicine & Hod, Sir Syed College of Medical Sciences, Karachi



Prof. Massimo Massi Benedetti, MD, (Italy)

- Professor Massimo Massi-Benedetti, Former Positions: Associate Professor of Endocrinology and Metabolic Diseases, Chair of the School of Pedology, of the School of Nursing Sciences and Member of the Academic Senate at the University of Perugia (Italy), Chair of the Coordination Office of the Umbria Regional Reference Centre for Diabetes; Co-Director of the WHO Collaborating Centre for Improvement of Diabetes Care. Chair of the IDF European Region from 1997 to 2003 and IDF Vice-President from 2003 to 2009, Chairman of the IDF Science Task Force 2009-2012, Director of Research and Education at the Dasman Institute for Diabetes Research in Kuwait (2007-2009).
-
- At Present He is President and Scientific Director of the HUB for International health Research-HIRS (www.HIRS-research.eu), Senior IDF Program Advisor and Member of the IDF Presidential Advisory Board,

Chairman of the Scientific Committee of the Associazione Italiana per la Difesa degli Interessi dei Diabetici (AIDID) (Italian Association for the Protection of the Interests of People with Diabetes).

- Professor Massi-Benedetti's Areas of Interest in The Field of Diabetes Include: Pathophysiology; Evaluation of New Drugs; Advanced Systems for Insulin Delivery; Complications; Pregnancy; Metabolic Monitoring; and Epidemiology, Diabetes Registries. He was a Member of the European Union Research Projects EURODIABETA; DIABCARD 1-4; DIABCARE 1-3; MFIT; DIABSTYLE 1-2; ADICOL, IMMIDIAB, PARENT, CHRODIS, BRIDGE Health and Project leader of the B.I.R.O. and EUBIROD EU Projects (www.eubirod.eu)
- Professor Massi-Benedetti is a Member of Several National and international Diabetes Societies, Has Organized, Chaired and Delivered Lectures at More Than 300 National and International Meetings. He is a Founder and Member of Various EASD Study Groups. He is the Author of More Than 350 Publications (Full Papers, Abstracts and Book Chapters) and Has Sat on the Editorial Boards of Numerous Peer-Reviewed Journals.



Prof. Mick Kumwend, (UK)

- MSC FRCP (London) FRCP (Edinburgh)
- He is Consultant Nephrologist and Clinical Director in Renal and Diabetes Centre Glan Clwyd Hospital - Rhyl Denbighshire United Kingdom
- Prof. Mick's Research Interests Include Diabetic Kidney Disease: Progression of CKD, Cognitive Dysfunction, The Role of the Kidney in Glucose Metabolism and Management of End Stage Kidney Disease in People with Diabetes.



Prof. Nebojša M. Lalić (Bosnia)

- (1958), MD, PhD, FRCP, is Currently Professor of Internal Medicine at the Faculty of Medicine, University of Belgrade as well as Director and Head of the Department for Metabolic Disorders, Intensive Treatment and Cell Therapy in Diabetes, Clinic for Endocrinology, Diabetes and Metabolic Diseases, Clinical Centre of Serbia in Belgrade.
- Professor Lalić Graduated in 1982 at Faculty of Medicine in Belgrade where he Completed Residency in Internal Medicine in 1990, as well as his PhD Thesis in 1993. In 1991, he was a Visiting Scientist at the Clinical Research Section and Immunology Section, Joslin Diabetes Center, Boston, USA. The Principal Interest of Professor Lalić Scientific Work in Diabetology/Endocrinology has been Concentrated on The Relationship between Insulin Secretion and Insulin Sensitivity Impairments in Type 2 Diabetes, Their Relevance for the Pathogenesis of Diabetes and its Late Complications and the Possibilities of

their Therapeutic Modulation (Especially Insulin Pump Treatment). In this Context, he is Also Intensively Involved in the Metabolic Studies of the Possibilities of Early Detection and Prevention of Type 2 Diabetes, as well as of the Late Diabetic Complications and Comorbidities, Especially coronary heart disease, ischemic stroke and Neurodegenerative Disorders. Professor Lalić has been Involved in More Than 200 Papers in Extenso in International Journals, Chapters, Monographies and Textbooks. He has been an Investigator in Several National and International Projects, Reviewer at Many International Meetings or Journals.

- Professor Lalić has been Chair of the National Expert Committee for Diabetes from 2002. Moreover, he is Member in Several National and International Medical Associations and Societies. Until Now he Chaired Organizing Committee of Three EASD Postgraduate Courses in Belgrade. Also, he is at Present Member of the Board of the IDF Europe.
- From 2012 he is the Dean of the Faculty of Medicine University of Belgrade. In Addition, he has been Elected for Corresponding Member in 2006 and for the Full Member of the Serbian Academy of Sciences and Arts in 2012.



Prof. Rayaz A. Malik, (UK)

He Graduated in Medicine from the University of Aberdeen in 1991, Obtained his MRCP in 1996, PhD from the University of Manchester in 1997 and was Elected to Become a Fellow of the Royal College of Physicians in 2007. He was Appointed as Consultant Physician and Senior Lecturer in 2001 and as Professor of Medicine and Consultant Physician in 2008 in Central Manchester University Teaching Hospitals and the University of Manchester. He was Appointed as Professor of Medicine at Weill Cornell Medicine in 2014 and is an Honorary Professor of Medicine and Consultant Physician at Central Manchester University Teaching Hospitals and University of Manchester and Visiting Professor of Medicine at Manchester Metropolitan University. He was Appointed as the Organizational Official for Weill Cornell Medicine in Qatar in November 2016. Over the last 15 years he has Pioneered the Use of Corneal Confocal Microscopy, A Non-Invasive Ophthalmic Instrument, to Quantify Diabetic and

other Peripheral Neuropathies. More Recently He has Applied CCM to Establish it as a Surrogate for Neuronal Damage in Patients with Stroke, Multiple Sclerosis, Parkinson's Disease and Dementia. He was the President of Neurodiab (The Diabetic Neuropathy Study Group of the EASD) from 2009-2012. He is an Associate Editor for Diabetic Medicine (2006 to Present); J of Diabetes and its Complications (2012-Present), PLOS One (2016- Present), BMC Neurology (2009-Present) and Advances in Therapy (2009- Present). He is on the Juvenile Diabetes Research Foundation Complications and Clinical Investigation Research Committee (2005-Present).



Prof. Sehnaz Karadeniz (IDF Europe/Turkey)

- President-Elect of the International Diabetes Federation European Region (IDF Europe).
- President of IDF Europe in 2015.
- An Ophthalmologist, Sehnaz has been Actively Involved in the Field of Diabetes for the past 20 Years in a Series of Medical, Scientific and Social Projects at both National and International Levels.
- Sehnaz Karadeniz Joined the Board of IDF Europe in 2007, where she has Worked on Political Affairs – Mainly Related to the World Health Organization European Region and the Council of Europe. Her Portfolio Also Includes Coalitions Such as the ECDA – the European Chronic Disease Alliance.
- She is also Board Member and Coordinator for International Relations for Diabetes 2020: Vision and Targets for Turkey, a Nationwide Project Supported by IDF Europe and WHO European Region and she Sits on the Board of the Nationwide Let's Stop Diabetes! Project Carried Out Under the Auspices of the Turkish Presidency.
- Sehnaz Graduated in Ophthalmology from the University of Istanbul and is Professor of Ophthalmology at the Istanbul Bilim University.



- **Prof. Dr. Shabeen Naz Masood (Pakistan)**
- A Graduate of the Dow University of Health Sciences in Pakistan. Presently Working as Professor & Head Department of Obstetrics and Gynaecology Isra University Karachi-Campus.
- She is also the Member of the Governing Body and Join Secretory of Diabetic Association of Pakistan, WHO Collaborating Centre.
- She is the Executive Member of Diabetes in Asia Study Group (DASG). She is also the Member of Governing Body of Health Research Advisory Board of Pakistan. She is Serving as an Executive Member in the in the Academic Committee of Society of Obstetricians and Gynecologists of Pakistan. Presently has the Honor of Serving as a Chairperson of Insulin Centenary Working Group of IDF-MENA Region.
- She has Twenty-Four Years of Academic, Clinical, Research and Teaching Experience. She is an Examiner for Obstetrics & Gynecology at College of Physicians and Surgeons of Pakistan (CPSP) and The Facilitator for Communication Skills at CPSP.
- An Author of Multiple Research Publications in Both National and International Medical Journals.
- Dr. Masood is the Principal Investigator from Pakistan for Many National and International Research Projects, Including the Coronis International Trail Study from National Perinatal Epidemiology Unit, University of Oxford UK, (2007-2015). She was Principal Investigator for the Projects on Gestational Diabetes Mellitus Prevention and Control Program-Pakistan, Funded by the World Diabetes Foundation Denmark. (2015-2019).



Prof. Tatjana Milenkovic (Macedonia)

- Professor of Internal Medicine at the University "St Cyril and Methodius", Medical Faculty in Skopje. She works at the Clinic of Endocrinology, Diabetes and Metabolic Diseases since 1985, Where in 1995 She has Established the Department of Education of People with Diabetes - and She has been Head of the Department Ever Since. She is a Member of the Executive Committee of Diabetes Education Study group (DESG). She is the President of Macedonian Diabetes Association, since 2013, the President of the Macedonian Scientific Association of Endocrinologists and Diabetologists since 2014 and Member of IDF Europe Board for Biennium 2020/2021.



Prof. Jamal Belkhadir (Morocco)

- Former Professor, Department of Internal Medicine at the University of Rabat.
- Former Head of the Ibn Sina University Hospital in Rabat.
- Specialist in Endocrinology and Metabolic Diseases, Fields Extend to Diabetes, Obesity, Metabolic Syndrome and the Ramadan fast.
- Chairman of the Working Groups on Moroccan Guidelines for Type 1 Diabetes (2011), Type 2 Diabetes (2013) and the Insulin Pump (2013).
- Honorary Member of Francophone Diabetes Association.
- Vice President of African Francophone Society of Diabetology.
- Member of Diabetes in Asia Study Group.
- President of the Moroccan League for the Fight against Diabetes.
- Chairman of IDF MENA Region.



Prof. Mohamad El Sandid MD, (Lebanon)

IDF MENA Region President Elect


- President of the Lebanese Diabetes Association (IDF Member – Since 1999)
- Founder and Manager of the National Diabetes Program (MOH) (2006-2013)
- Decision Maker of the Diabetes Advisory Board in the National Diabetes Committee (MOH),
- Former Member of the Executive Board of Pan Arab Group for the Study of Endocrinology and Diabetes,
- Ex Member of the Executive Board of the Endocrine Society,
- Ex Member of the Executive Board of the Infertility Society,
-Assistant Professor of Internal Medicine, Lebanese University,
-Member of the American Diabetes Association Middle East Insulin and Neuropathy Working Group.
- Member of the DASG (Diabetes in Asia Study Group).
- Member of the International Humanitarian and Disaster Committee IDF- 2017
- MENA -IDF Representative in Steering Committee Members 2017
-Nomination for the Post of MENA/IDF Regional Chair Elect 2020

- Participated in Many Clinical Studies and Researches in the field of Diabetes and Endocrinology,
- Main Organizer of the "Diabetes WS Education" Held Under the Patronage of the Ministry of Public Health and World Health Organization, Contributor in Congresses and Symposia, as well as Continuous Medical Education Programs.
- Chairman and Speaker of National and International Scientific Conferences
- Publisher of more than 60 Booklets and Papers
- Lecturer: Over 40 Scientific Lectures per Year Addressed to Physicians Targeting Different OAD Insulin and Other Diabetes Molecules.
- 2019- 2020 Ongoing Project IN Collaboration with WDF and IDF (Diabetic Screening for Low Income in Lebanon)
-Adviser and Committee Member on Many Doctorates' Thesis in the Lebanese, USJ Medical Universities

Current work:

- Endocrinologist and Internist of the Ministry of Defense-Saida
- Beit Eddine-Iklim /Lebanon with the Lebanese Army.
- Endocrinologist of the General Security - Beirut – Lebanon
- Endocrinologist of the security Forces
- Endocrinologist at Labib Medical Center –Saida -Lebanon

Owner of a Private Clinic in Beirut Makassed Center and in Saida Nejmeh Square



Prof. Abdelmjid Chraibi (Morocco)

- Interim Dean of the Medical School of Medicine & Pharmacy
- Ibn Zohr University, Agadir-Morocco Endocrinologist, Diabetologist
- Mohammed V Souissi University, Rabat, Morocco
- Professor Abdelmjid Chraibi has been Head of Diabetes, Endocrinology and Nutrition at Avicenna Hospital, Rabat since 2006.
- Professor Chraibi's main research interests include goiter, insulin therapy, hypoglycemic agents and medullary thyroid cancer
- and he has collaborated with international organizations including the World Health Organization. He has authored over 100 articles in Arabic and international scientific journals and has been involved with a number of national and international societies as President of the Moroccan Society of Diabetes, Endocrinology and Nutrition between 2006 and 2009; member of the Mediterranean Group Study of Diabetes; and member of the Arabic Association for the Study of Diabetes.
- Professor Chraibi is also actively involved in charitable organizations dealing with health problems in remote rural areas in Morocco.



Prof. Abdel Razak Al Madani (UAE)

- Dr. Abdulrazzaq Ali Al Madani is Consultant in Medicine and Endocrinology at Al Borj Medical Centre in Dubai. After graduating in Medicine from the Ain Shams University in Cairo, Dr. Madani pursued his Postgraduate training in Internal Medicine and Endocrinology from Munich, Germany and obtained his Fachartz in both specialties. The Royal College of Physicians endowed Dr. Madani Honorary Fellowships from their Colleges in Edinburg and Glasgow.
- Dr. Madani joined Dubai Health Authority in 1980 and from the year 1993, has held the post of Consultant in Medicine and Endocrinology in Dubai Hospital. He was the Chief Executive Officer (CEO) of Dubai Hospital – a tertiary care facility under the Dubai Health Authority – from October 2009 to March 2014.
- He has vast experience in the management of diabetes and endocrine disorders, especially thyroid gland, he has carried out more than 40,000 thyroid sonography and over 10,000 fine needle aspirations of thyroid nodules, and he has been trained in Radio Frequency ablation and laser ablation of benign thyroid


nodules.

- Dr. Madani was awarded the Sheikh Rashid Award for Scientific Achievement in 1988 and was honored with the Dubai Government Excellence Award (DGEP) in 2002 under the Category – Distinguished Employee. Dr. Madani is the President of the Emirates Diabetes Society and the President of the Gulf Group for Study of Diabetes. He is the Editorial Board Chairman of the "Diabetes Positive Living Magazine" a social initiative of the Emirates Diabetes Society.
- He has acted as the chairman of the local organizing committee of IDF Congress in Dubai 2011 and is the chairman of the local organizing committee at the coming IDF Congress in Abu Dhabi 2017. His publications in Clinical Diabetes include "Recommendations for Management of Diabetes During Ramadan", "Diabetes Care, Algorithm for Management of Type 2 in the Middle East", "Diabetes Education in the Arab World, A Call for Action" , Driving and diabetes mellitus in the Gulf Cooperation Council countries: Call for action. and "UAE National Diabetes Guidelines 2008 and 2011", and Diabetes and Ramadan: Practical Guidelines (IDF/DAR).



Prof. Asaad Aldaftar (Bahrin)

- Consultant Internist & Endocrinologist.
- Fellow of Royal College of Physicians
- Member of Society of Endocrinology United Kingdom
- Fellow of Iraq Council of Medical Specialties.



Prof. Bashir Tarazi (Palestine)

- President Diabetes, Palestine
- National Representative at D-Foot International & IWGDF
- Task Force Diabetic Foot MENA Region IDF
- Train the Trainer at DAR International Alliance
- MD Medicine, Aristotle University Thessaloniki/Greece (December/1977)
- Internal Medicine 1979-1985 Government Hospital Jerusalem Postgraduate
- Training on Diabetes and Complications at Royal infirmary Glasgow and Manchester UK 1988/1993 British Council Scholar
- Lecturer at Continuous Medical Education at Diabetes School, Member at Local and International Diabetes Association, Participation at Observational Clinical Research for Insulin Dpp4 and Glp1
- Consultant Diabetologist at Sick Funds & Private Clinic - Independent (26 Years 3 Months) July/1995 -
- Chief Diabetologist - Augusta Victoria Diabetes Center (10 Years 3 Months) August/2005 - October/2015
- Chief Diabetologist UNRWA - Headquarter West Bank (4 Years 3 Months) July/1991
- -September/1995




Prof. Dalal Alromaihi (Bahrain)

- Head of Department of Internal Medicine and Consultant Endocrinologist at King Hamad University Hospital
- Prof. Alromaihi Obtained her MD Degree with Honors Distinction from Arabian Gulf University
- Prof. Alromaihi has the American Board Certification in Both Internal Medicine and Diabetes, Endocrinology and Metabolism.
- Worked as a Consultant Endocrinologist at Yuma Regional Medical Center in Arizona, USA until she Moved Back to Bahrain in 2014 and Joined King Hamad University Hospital as a Consultant Endocrinologist and Program Director of Saudi Board Internal Medicine Residency Program. She is Currently Serving as an Associate Professor at the Royal College of Surgeons Ireland – Bahrain and was Awarded the Best Senior Clinical Lecturer in 2016.
- She is a Member of the National Committee for Combating Noncommunicable Disease in the Kingdom of Bahrain and a Board Member and Chair of Scientific Committee at Bahrain Medical Society



Prof. Hamdoun Lhassani (Morocco)

- A Specialist in Endocrine & Diabetes
- A Graduate of the University of Lille and Amiens, France
- Previously Worked at University Hospitals in Northern France
- Vice-President of the Moroccan Association for Endocrine Diseases, Nutrition and Diabetes
- Former Head of the Moroccan Association for Endocrine Diseases, Nutrition and Diabetes
- Participant in Several Medical Studies
- A Member of the Francophone Association for Diabetes
- A Member of the European Association for the Study of Diabetes
- President of the Association of the City of Salé in Morocco to Help Diabetics
- Treasurer of the National Federation of Moroccan diabetics.



Prof. Hanaa AlGhanem (Syria)

- Graduated from Medical University of Damascus in 1985. Had Endocrine Specialty from Paris 5; France in 1990.
- Working in Almouassat University Hospital Since 1993 till now. And I'm the Chief of Endocrinology Department Since 2014 till now. The president of Syrian Diabetes Association since 2015. In the Endocrine Society I Worked 6 Years (3 as a Secretory. And 3 as Accountant).



Prof. Hazim Abdulrazak (Iraq)

President of the Iraqi Diabetes Association
Former Professor and Consultant Internist Almustansiriya College of Medicine
Currently Consultant Internist in the Red Crescent Hospital-Baghdad



Prof. Kebira Benabed (Morocco)

Endocrinologist Diabetologist
Professor of Internal Medicine - Rabat University Hospital
Former Secretary General of Moroccan Society of Endocrinology, Diabetology and Nutrition
Member of the Board of the Moroccan League for the Fight Against Diabetes



Prof. Mohamed Hassanein (UK)

- Qualifications: MB ChB 1985 (Merit) Faculty of Medicine, Alexandria, Egypt.
- MRCP (UK) 1996 FRCP (London) 2006, FRCP (Edinburgh 2009)
- CCST (UK) 2002 Endocrinology, Diabetes & General Medicine
- MPhil Reading University, UK, 2005
- Professional Membership:
- Member of the AASD
- Member of Emirates Medical Association EMA & EDS
- Member of the British Medical Association -BMA
- Member of the Medical Defense Union
- Member of the British Endocrine Society- BES
- Member of the British Thyroid Association
- Member of Diabetes UK
- Member of the International Diabetes Federation - IDF
- Member of the of the EASD
- Member of the Educational Group of the EASD - DESG
- Clinical/Academic Posts:
- Senior Consultant Endocrinologist, Dubai Hospital, DHA, UAE
- H Senior Lecturer and Associate Director for Postgraduate Diabetes Education, Cardiff University, UK
- Lead Consultant in Endocrinology & Diabetes, Glan Clwyd



Prof. Nadima Shegem (Jordan)

- MB, JBIM, FACE, is a Consultant in Endocrinology and Diabetes.
- President of the Jordanian Society of the Care of Diabetes.
- Former Vice-President of the Jordanian Society of Endocrinology, Diabetes, and Metabolism.
- Head of the Camp Hope for Children with Diabetes.
- Published Various Scientific Papers and Experienced Lecturer.



Prof. Zayed Atef (Yemen)

- Professor of internal Medicine, Sana'a University
- President of Yemeni Diabetes Association
- Director of National Diabetes Center Sana'a

NATIONAL F

Abdel Khalek Hamed
Abir Zakaria
Adel Eletreby
Adham Osman
Ahmed Abdel Salam
Ahmed Bendary
Ahmed Hegab
Ahmed Magdy
Ahmed Rabiee
Ahmed Shawky
Ahmed Taha
Ali Abbasi
Ali Gaballa
Aliaa Alaghoury
Amal Fouad
Amin Roshdy
Amira Ahmed
Amr Abdel Wahab
Amr Elmeligi
Amr Fatin
Amr Gad
Amr Helmy
Amr Shaker
Ashraf Abo Bakr
Ashraf Reda
Assem Seif
Atef Basiouny
Atef Elbahry
Ayman El Menoufy
Bahaa Abbas
Bassem Zarif
Eman Medhat
Enayat Ezzat
Eslam Shawky
Fahmy Amara
Farid Fawzy
Gamal Esmat
Gamela Nasr
Hala Kahla
Hala Naguib Hosny
Hanaa Taha
Hanan Gawish
Hany Hamad
Hassan Hamdy
Haytham Badran
Hazem Ashmawy
Hazem Khamis
Heba Morad
Hesham Magd Eldin
Hisham Habib
Hoda Gouda
Hosny El Fayomy
Hosny Salama
Hossam Ghazy
Hossam Zaki
Hussein El Fishawy
Ihab Hana
Iman El Sherif
Iman El Shorbagy
Iman Kamel
Inass Shaltout
Khalid El Hadidy

FACULTY (ALPHABETICALLY)

Lobna Eltouny
Mabaheg Souka
Magdy Abdel Hamid
Magdy El Dahshan
Magdy Helmy
Maha Assem
Maha Yousef
Mayada Mousa
Mazen Attia
Medhat El Sahhar
Megahed Abo El Magd
Moghazy Mahgoub
Mohamed Alboraie
Mohamed Fahmy Abdel Aziz
Mohamed Hassanein
Mohamed Naguib Wi Fi
Mohamed Reda Halawa
Mohsen Ibrahim
Mona Amin
Mona Atteya
Mona Elamir
Mona Roshdi
Mona Yousry
Mostafa A. Hassanein
Nancy Elbarbary
Nehal Hamdy
Omar El Saadny
Omar Hiekal
Raafat Rashwan
Rasha Sobh
Rawia Khater
Sahar Elheiny
Sameh Shaheen
Samir Helmy Assad
Samir Naim Assad
Sayed Gad
Shaymaa Abdelmaboud
Shereen Abdelghaffar
Sherif Hafez
Sherif M. Abdel Fattah
Soha Abdel Dayem
Soliman Nasr
Tarek Fayad
Walaa Anwar
Yasser Abdel Hamid
Yehia Ghanem
Zeinab Sabra

AGE





AASD 2021

NDA



مؤتمر خالي من الكورونا

AGENDA

TUESDAY
26 OCTOBER
2021

09:00 - 10:00 REGISTRATION

SESSION 1 10:00 - 11:00 — Hall A Cleopatra

Diabetes and Endocrine Department Faculty of Medicine, Cairo University

CHAIRPERSONS: *(Alphabetically)*

Prof. Amr. El Meligy *(Cairo University)*
Prof. Assem Sief *(Cairo University)*
Prof. Heba Morad *(Cairo University)*
Prof. Hesham Magd Eldin *(Cairo University)*
Prof. Soliman Nasr *(Cairo University)*

	SESSION	SPEAKER
15 Min	Management of Diabetes in the ICU Setting	Prof. Maha Youssif *(Cairo University)*
15 Min	Management of Diabetes in Hospital Setting	Prof. Maha Assem *(Cairo University)*
15 Min	Acute Hyperglycemic Emergencies	Prof. Ahmed Rabiee *(Cairo University)*
15 Min	Discussion	

SESSION 2 11:05 - 12:00 — Hall A Cleopatra

Diabetes in Children and Youth

CHAIRPERSONS: *(Alphabetically)*

Prof. Mona Atteya *(Cairo University)*
Prof. Shereen Abdelghaffar *(Cairo University)*
Prof. Soha Abdel Dayem *(National Research Center)*

	SESSION	SPEAKER
15 Min	Screening and Management of Type 2 Diabetes in Youth.	Prof. Shereen Abdelghaffar *(Cairo University)*
15 Min	The Threat of Co-Morbidities in Youth with Type 2 Diabetes.	Prof. Mona Atteya *(Cairo University)*
15 Min	Update in Management of Stressful Conditions of Type 1 Diabetes in Children and Adolescents.	Prof. Soha Abdel Dayem *(National Research Center)*
10 Min	Discussion	

12:00-12:20 Coffee Break

SESSION 3 12:25 - 13:40 — Hall A Cleopatra

AASD Nephrodiab Study Group

CHAIRPERSONS: *(Alphabetically)*

Prof. Hisham Magd El Din	*(Cairo University)*	Prof. Raafat Rashwan	*(Zagazig University)*
Prof. Mostafa A. Hassanein	*(Military Medical Academy)*	Prof. Tarek Fayad	*(Cairo University)*
Prof. Nehal Hamdy	*(Cairo University)*	Prof. Yasser Abdel Hamid	*(Cairo University)*

	SESSION	SPEAKER
20 Min	GLP-1 Agonists and the Kidney	Prof. Amr. El Meligy *(Cairo University)*
15 Min	Metformin, a Nephrologist View	Prof. Mona Roshdi *(Cairo University)*
15 Min	New KDIGO Guidelines for DKD	Prof. Hany Hamad *(Cairo University)*
15 Min	Obesity and Chronic Kidney Disease	Prof. Amr. Shaker *(Cairo University)*
10 Min	Discussion	

SESSION 4 13:45 - 14:35 — Hall A Cleopatra

CHAIRPERSONS: *(Alphabetically)*

Prof. Hisham Habib	*(Cairo University)*	Prof. Raafat Rashwan	*(Zagazig University)*
Prof. Hisham Magd El Din	*(Cairo University)*	Prof. Zeinab Sabra	*(Cairo University)*

Nerhadou Symposium

	SESSION	SPEAKER
15 Min	Nerhadou Symposium	

Karman Pharma Symposium

	SESSION	SPEAKER
10 Min	Role of Phenolic Component of Charantia Momordica in Insulin Resistant Collective Study	

Scientific & Trading Symposium

	SESSION	SPEAKER
15 Min	Prolonged Fasting Mimicking Diet; A Major Intervention to Reverse Cellular Aging and Support Metabolic Health.	Prof. Osama Hamdy, *(USA)*

Apex Pharma Symposium

	SESSION	SPEAKER
10 Min	SGLT2i ... Clinical Tips & Tricks	Prof. Ihab Salem (Zagazig University)

SESSION 5 14:45 - 15:30 — Hall A Cleopatra

CHAIRPERSONS: *(Alphabetically)*

Prof. Hisham Habib *(Cairo University)*
Prof. Hisham Magd El Din *(Cairo University)*
Prof. Raafat Rashwan *(Zagazig University)*
Prof. Zeinab Sabra *(Cairo University)*

HPG Symposium

	SESSION	SPEAKER
15 Min	Pivastalo: The Hidden Gem	

Al Mokhtabar Symposium

	SESSION	SPEAKER
10 Min	Laboratory Update in Almokhtabar	

ELborg Lab Symposium

	SESSION	SPEAKER
15 Min	Overview of Elborg Lab	

MultiCare Symposium

	SESSION	SPEAKER
15 Min	Is Empagliflozin Solution For Diabetes Dilemma	Prof. Abir Zakaria

SESSION 6 10:20 - 12:00 Hall B Teba Hall

Conference Paper Presentation (I)

CHAIRPERSONS: *(Alphabetically)*

Prof. Hisham Magd El Din *(Cairo University)*
Prof. Nehal Hamdy *(Cairo University)*
Prof. Raafat Rashwan *(Zagazig University)*
Prof. Yasser Abdel Hamid *(Cairo University)*
Prof. Zeinab Sabra *(Cairo University)*

	SESSION	SPEAKER
10 Min	A High Incidence of New Onset Diabetes Among Patients with COVID-19 Admitted to Hospital	Dr. Majid H Alabbood *(Iraq)*
10 Min	Discussion	
10 Min	The Role of Circulating Soluble Fms-Like Tyrosine Kinase-1 In Patients with Diabetic Foot Ulcer: A Possible Mechanism of Pathogenesis Via a Novel Link Between Oxidative Stress, Inflammation and Angiogenesis	Dr. Yasser M Hafez *(Tanta University)*
10 Min	Discussion	
10 Min	Preparation and Evaluation of Novel Anti-Obesity Immunoglobulins for Immunoprophylaxis and Therapy	Dr. Manal Moh. Elsayed *(National Research Centre)*
10 Min	Discussion	
10 Min	Role of MicroRNA as a Marker in Detection of Diabetic Nephropathy in Type 2 Diabetic Egyptian Patients	Dr. Elsayed Ghonamy *(Ain Shams University)*
10 Min	Discussion	
10 Min	Evaluation of Physicians` Approaches for the Management of Patients with Diabetes during Ramadan in Iraq	Dr. Majid H Alabbood *(Iraq)*
10 Min	Discussion	
12:05-12:25 Coffee Break		

SESSION 7 12:30 - 13:50 | Hall B Teba Hall

Conference Paper Presentation II

CHAIRPERSONS: *(Alphabetically)*

Prof. Abdelkhalek Hamed *(Military Medical Academy)*
Prof. Hisham Habib *(Cairo University)*
Prof. Maha Assem *(Cairo University)*
Prof. Maha Yousef *(Cairo University)*
Prof. Zeinab Sabra *(Cairo University)*

	SESSION	SPEAKER
10 Min	Role of Resistin, IL-6 and NH2-Terminal Portion-ProBNP in Cardiac Pathogenesis in Patients with Diabetes Mellitus	Dr. Mohamed Abdel-Samiee *(National Liver Institute)*
10 Min	Discussion	
10 Min	Obesity and Waist Circumference are Possible Risk Factors for Thyroid Cancer: Correlation with Different Ultrasonography Criteria	Dr. Marwa Sayed Eissa *(Cairo University)*
10 Min	Discussion	
10 Min	Correlation between Serum Neopterin Level and Carotid Artery Intima- Media Thickness in Type 2 Diabetic Patients	Dr. Mohamed Abdel Hamid Moh. Mahmoud
10 Min	Discussion	
10 Min	A Study on Diabetes in Ramadan in Iraq	Dr. Majid H Alabbood *(Iraq)*
10 Min	Discussion	

SESSION 8 13:55 – 14:45 | Hall B Teba Hall

Conference Poster Presentation

	SESSION	SPEAKER
	Adipokines at the Crossroad between Obesity and Type 2 Diabetes Mellitus	Dr. Ahmed M. A. Akabawy
	Influence of Prediabetes on Hospital Outcome after Coronary Artery Bypass Grafting	Dr. Yasser Shaban Mubarak
	Biological Effects of Human Amniotic Membrane Products on Diabetic Foot Ulcers: A Systematic Review and Meta-Analysis Grafting	Dr. Mohamed Ibrahim Gbreel
	Prevalence and Risk Factors of Peripheral Neuropathy in Type 2 Diabetic Patients at Benghazi Diabetic Centre	Dr. Mona Adeeb Khalil
	How to Manage Gestational Diabetes and Hashimoto Thyroiditis in a Woman	Dr. Anila Rrupulli *(Albania)*
	Sex Steroids in Association with PAD in Elderly Men	Dr. Ahmed Adel Mohamed
	Reduced Glycemic Variability with Once-Weekly Semaglutide vs. Active Comparators in Post-hoc Analysis of the SUSTAIN Program	Dr. Richard E. Pratley

WEDNESDAY
27 OCTOBER
2021

SESSION 9 09:00 - 09:50 — Hall A Cleopatra

Diabetes & Economic Burden

CHAIRPERSONS: *(Alphabetically)*

Prof. **Bassem Zarif** *(National Heart Institute)*
Prof. **Hanan Gawish** *(Mansoura University)*
Prof. **Hazem Ashmawy** *(Zahzaeg University)*
Prof. **Mohamed Sandid** *(Lebanon)*

	SESSION	SPEAKER
15 Min	Cost effeteness of diabetes therapies	Prof. Iryna Vlasenko *(Ukrania)*
15 Min	Diabetes and Value Based Health Care	Prof. Massimo Massi Benedetti *(Italy)*
15 Min	Diabetes Technology	Prof. Evgenia Patrakeeva *(Russia)*
5 Min	Discussion	

SESSION 10 09:55 - 11:40

Hall A Cleopatra

EGYPTIAN SOCIETY OF CARDIOLOGY

The Egyptian Society of Cardiology Symposium
A Case-Based Guideline-Directed Interactive Discussion

CHAIRPERSONS: *(Alphabetically)*

Prof. Adel Eletriby *(Ain Shams University)*
Prof. Khaled Shokry *(Military Academy)*

PANELISTS: *(Alphabetically)*

Prof. Ahmed Hegab *(National Heart Institute)*
Prof. Eslam Shawky *(Alazhar University)*
Prof. Gamela Nasr *(Suez Canal University)*
Prof. Magdy Abdel Hamid *(Cairo University)*
Prof. Sameh Shaheen *(Ain Shams University)*

	SESSION	SPEAKER
15 Min	Introduction and Case Presentation: How is Diabetes Associated with CVD Risk	Prof. Gamela Nassr *(Suez Canal University)*
5 Min	Panel Discussion	
15 Min	How to Risk Stratify Diabetic Patient for Future CV Events	Prof. Sameh Shaheen *(Ain Shams University)*
5 Min	Panel Discussion	
15 Min	Should Metformin be the First Line Therapy in Type 2 Diabetes?	Prof. Adel Eletreby *(Ain Shams University)*
5 Min	Panel Discussion	
15 Min	Treatment of Heart Failure in Diabetic Patients	Prof. Magdy Abdel Hamid *(Cairo University)*
5 Min	Panel Discussion	
15 Min	Revascularization in a Patient with DM	Prof. Ahmed Magdy *(National Heart Institute)*
10 Min	Take Home Messages, Conclusion and Discussion	

OPENING CEREMONY

11:45 - 12:10

Hall A Cleopatra

Prof. Andrew Boulton (UK)
IDF President

Prof. Akhtar Hussein (Norway)
IDF President Elect

Prof. Jamal Belkhadir (Morocco)
Chairman of IDF MENA Region

Prof. Mohamed Sandid (Lebanon)
IDF MENA Region President Elect

Prof. Raafat Rashwan
Conference Honorary President

Prof. Inass Shaltout
AASD & Conference President

Prof. Mohamed Hassanein
Conference Vice President

Prof. Abdel Khalik Hamed
Conference Secretary

AASD in 17 Years

SESSION 11 12:15 – 13:05 — Hall A Cleopatra

International Diabetes Federation

Opening Symposium
International Diabetes Federation (IDF)

CHAIRPERSONS: *(Alphabetically)*

Prof. Abdel Razak Almadani	*(UAE)*	Prof. Mohamed Sandid	*(Lebanon)*
Prof. Inass Shaltout	*(Cairo University)*	Prof. Rayaz Malik	*(UK)*
Prof. Jamal Belkhadir	*(Morocco)*		

	SESSION	SPEAKER
20 Min	Diabetes Neuropathy an Update for 2021	Prof. Andrew Boulton *(UK)*
20 Min	100 Years of Insulin Therapy: Challenges by Race and Ethnicity.	Prof. Akhtar Hussein *(NORWAY)*
10 Min	Discussion	

13:05-13:25 Coffee Break

SESSION 12 13:30 – 14:20 — Hall A Cleopatra

State of the Art Session

CHAIRPERSONS: *(Alphabetically)*

Prof. Ahmed Taha	*(Cairo University)*	Prof. Inass Shaltout	*(Cairo University)*
Prof. Amr Gad	*(Cairo University)*	Prof. Mohamed Hassanein	*(UK)*
Prof. Ihab Hana	*(National Diabetes Institute)*	Prof. Mohsen Ibrahim	*(Cairo University)*

	SESSION	SPEAKER
20 Min	Evidence Based Management of Diabetic Foot Problems	Prof. Andrew Boulton *(UK)*
20 Min	Psychology of Diabetic Foot Ulcer Development of Healing	Prof. Loretta Vileikyte *(UK)*
10 Min	Discussion	

SESSION 13 14:25 – 15:20 Hall A Cleopatra

EAVA

Egyptian Association of Vascular Biology and Atherosclerosis

CHAIRPERSONS: *(Alphabetically)*

Prof. Ashraf Reda *(EAVA President, Menoufia UN.)*

Prof. Atef Elbahry *(EAVA Vice President, Port Said)*

	SESSION	SPEAKER
15 Min	**Pcsk9 & Diabetes**	**Prof. Atef Elbahry** *(EAVA Vice President, Port Said)*
15 Min	**Interplay between Diabetes and Heart Failure**	**Prof. Ahmed Shawky** *(Ain Shams University)*
15 Min	**The Egyptian 'CardioRisk' Project; are We Managing our Patients with ACS Property?**	**Prof. Ahmed Bendary** *(Benha University)*
10 Min	**Discussion**	

SESSION 14 15:25 – 16:05 Hall A Cleopatra

SANOFI SYMPOSIUM SANOFI

CHAIRPERSONS: *(Alphabetically)*

Prof. Farid Fawzy *(Zagazig University)*

Prof. Hossam Ghazy *(Mansoura University)*

Prof. Lobna Eltouny *(Assiut University)*

Prof. Sherif Hafez *(Cairo University)*

Prof. Walaa Anwar *(Assiut University)*

	SESSION	SPEAKER
20 Min	**Advancing Basal Insulin Therapy in the Solimix Trial: Comparing IGlarlixi to Premixed Insulin**	**Prof. Inass Shaltout** *(Cairo University)*
20 Min	**B-Right from the Start**	**Prof. Walaa Anwar** *(Assiut University)*
16:10-16:30 Coffee Break		

SESSION 15 16:35 – 17:15 | Hall A Cleopatra

MSD SYMPOSIUM MSD

CHAIRPERSON & MODERATOR:

Prof. Sherif Hafez *(Cairo University)*

CHAIRPERSONS: *(Alphabetically)*

Prof. Farid Fawzy *(Zagazig University)*
Prof. Khalid El Hadidy *(Beni Suef University)*
Prof. Mabaheg Souka *(Alexandria University)*
Prof. Megahed Abo El Magd *(Mansoura University)*
Prof. Walaa Anwar *(Assiut University)*

	SESSION	SPEAKER
	Initiating Oral Therapy: Role of Sitagliptin	Prof. Amr Abdel Wahab *(Menia University)*
	Role of Sitagliptin in Later Stage Type 2 Diabetes	Prof. Omar El Saadny *(Cairo University)*

SESSION 16 17:20 – 18:20 | Hall A Cleopatra

Diabetes Burdeu

CHAIRPERSONS: *(Alphabetically)*

Prof. Atef Elbahry` *(EAVA Vice President, Port Said)*
Prof. Hazem Khamis *(Military Medical Academy)*
Prof. Hossam Ghazy *(Mansoura University)*
Prof. Inass Shaltout *(Cairo University)*
Prof. Mohamed Naguib *(Cairo University)*

	SESSION	SPEAKER
17 Min	Diabetic Neuropathy	Prof. Rayaz A. Malik *(UK)*
17 Min	Glycaemic Control, are We Achieving Targets? A Review of Regional Data.	Prof. Mohamed Hassanien *(UK)*
17 Min	Transition from Pediatric to Adult Diabetes Care.	Prof. Evgenia Patrakeeva *(Russia)*
5 Min	Discussion	

SESSION 17 18:25– 19:10 Hall A Cleopatra

CHAIRPERSONS: *(Alphabetically)*

Prof. Abde Ikhalek Hamed *(Military Medical Academy)*
Prof. Hazem Ashmawy *(Zagazig University)*
Prof. Mabaheg Souka *(Alexandria University)*
Dr. Sayed Gad

ALESRAA SYMPOSIUM

	SESSION	SPEAKER
10 Min	Imagine what the "X" can do	Prof. Magdy Helmy *(Alexandria University)*
5 Min	Discussion	

LIPTIS SYMPOSIUM

	SESSION	SPEAKER
10 Min	Dapaglflozin beyond glycemic control	Prof. Hala Kahla *(Cairo University)*
5 Min	Discussion	

UTOPIA SYMPOSIUM

	SESSION	SPEAKER
10 Min	Duloxeprin A New Era in Management Neuropathic Pain	Prof. Khaled El Hadidy *(Beni Suif University)*
5 Min	Discussion	

19:15 Lunch

THURSDAY
28 OCTOBER
2021

SESSION 18 09:00 - 09:40 — Hall A Cleopatra

Diabetes and the Mind

CHAIRPERSONS: *(Alphabetically)*

Prof. Dario Rahelic	*(Croatia)*	Prof. Hala Kahla	*(Cairo University)*
Prof. Evgenia Patrakeeva	*(Russia)*	Prof. Hazem Ashmawy	*(Zagazig University)*
Prof. Farid Fawzy	*(Zagazig University)*	Prof. Mohsen Ibrahim	*(Cairo University)*

	SESSION	SPEAKER
17 Min	Diabetes and Depression	Prof. Frans Pouwer *(Denmark)*
17 Min	Diabetes, Emotion and Decision Making	Prof. Tatjana Milenkovic *(Macedonia)*
5 Min	Discussion	

SESSION 19 09:45 - 10:55 — Hall A Cleopatra

CHAIRPERSONS: *(Alphabetically)*

Prof. Evgenia Patrakeeva	*(Russia)*	Prof. Mohsen Ibrahim	*(Cairo University)*
Prof. Hala Kahla	*(Cairo University)*	Prof. Tatjana Milenkovic	*(Macedonia)*
Prof. Hisham Magd El Din	*(Cairo University)*		

	SESSION	SPEAKER
20 Min	Inflammation in Type 2 Diabetes	Prof. Dario Rahelic *(Croatia)*
20 Min	Diabetes Treatments for Non- Diabetic Conditions	Prof. Andrew J Behnke *(USA)*
20 Min	Autoimmune Diabetes of the Adult	Prof. Rayaz A. Malik *(UK)*
10 Min	Discussion	

SESSION 20 11:00 - 11:40 — Hall A Cleopatra

SERVIER SYMPOSIUM

CHAIRPERSONS: *(Alphabetically)*

Prof. Ahmed Abdel Salam
Prof. Hany Hamad *(Cairo University)*
Prof. Rawia Khater *(Cairo University)*
Dr. Sayed Gad
Prof. Yahia Ghanem *(Alexandria University)*

	SESSION	SPEAKER
20 Min	SU a cornerstone to achieve control	**Prof.** Magdy Helmy *(Alexandria University)*
20 Min	Optimum management of hypertensive diabetic patients	**Prof.** Gamila Nasr *(Suez Canal University)*

SESSION 21 11:45 - 12:25 — Hall A Cleopatra

BOEHRINGER INGELHEIM SYMPOSIUM

CHAIRPERSONS: *(Alphabetically)*

Prof. Abir Zakaria *(Cairo University)*
Prof. Amr Abdel Wahab *(Menia University)*
Prof. Raafat Rashwan *(Zagazig University)*
Prof. Rawia Khater *(Cairo University)*

	SESSION	SPEAKER
20 Min	Management of Type-2 Diabetes What Synjardy Can Add	**Prof.** Inass Shaltout *(Cairo University)*
20 Min	Jardiance a Game Changer in Management of HFrEF	**Prof.** Haytham Badran

SESSION 22 12:30 - 13:30 — Hall A Cleopatra

SANOFI SYMPOSIUM

CHAIRPERSONS: *(Alphabetically)*

Prof. **Ahmed Abdel Salam**
Prof. **Ali Abbasi** *(Alexandria University)*
Prof. **Atef Basiouny** *(NIDE)*
Prof. **Fahmy Amara** *(Alexandria University)*
Prof. **Sherif Hafez** *(Cairo University)*

	SESSION	SPEAKER
20 Min	**Beyond LDL Reduction: The Way Ahead in Dyslipidemia Management**	**Dr. Atef El Bahary** *(EAVA Vice President, Port Said)*
20 Min	**Dapagliflozin: Redefining Type 2 Diabetes Management**	**Dr. Omar El Saadany** *(Cairo University)*
20 Min	**The Ideal Rapid Partner**	**Dr. Amr. Abdelwahab** *(Menia University)*

SESSION 23 13:35 - 14:15 — Hall A Cleopatra

NOVARTIS SYMPOSIUM

CHAIRPERSONS: *(Alphabetically)*

Prof. **Amr Abdel Wahab** *(Menia University)*
Prof. **Atef Basiouny** *(NIDE)*
Prof. **Ayman Elmenoufy**
Prof. **Iman El Shorbagy** *(Zagazig University)*

	SESSION	SPEAKER
20 Min	**Managing Uncontrolled patients**	**Mohamed Reda Halawa** *(Ain Shams University)*
20 Min	**Time is Essential; So as Entresto**	**Prof. Atef Elbahry** *(EAVA Vice President, Port Said)*

14:15 -14:35 Coffee Break

SESSION 24 14:35 - 16:00 — Hall A Cleopatra

NOVO NORDISK SYMPOSIUM

CHAIRPERSONS: *(Alphabetically)*

Prof. Adham Osman
Prof. Iman El Sherif *(Suez Canal Universiy)*
Prof. Iman El Shorbagy *(Zagazig University)*
Prof. Mohamed Reda Halawa *(Ain Shams University)*
Prof. Yehia Ghanem *(Alexandria University)*

	SESSION	SPEAKER
20 Min	**Semaglutide Once weekly, Above & Beyond**	**Prof. Omar El-Sadaany** *(Cairo University)*
20 Min	**Degludec: The Quest for the Ideal Basal Insulin**	**Prof. Hala Kahla** *(Cairo University)*
20 Min	**IDegLira: The Power of the Dual Action**	**Prof. Farid Fawzy** *(Zagazig University)*
20 Min	**Liraglutide 3.0 mg SCALE-ing Up Obesity Management**	**Prof. Assem Seif** *(Cairo University)*

SESSION 25 16:00 - 16:30 — Hall A Cleopatra

ABBOTT SYMPOSIUM

CHAIRPERSONS: *(Alphabetically)*

Prof. Fahmy Amara *(Alexandria University)*
Prof. Inass Shaltout *(Cairo University)*
Prof. Jamal Belkhadir *(Morocco)*
Prof. Mohamed Fahmy Abdel Aziz *(Cairo University)*
Prof. Samir Helmy Assad *(Alexandria University)*

	SESSION	SPEAKER
30 Min	**Breakthrough Solutions for Diabetic retinopathy patients in 2021** **Fenofibrate Nanocrystals Technology. Now in Egypt!**	**Prof. Samir Helmy Asaad** *(Alexandria University)*

SESSION 26 16:35 – 16:55 | Hall A Cleopatra

MERCK SYMPOSIUM

CHAIRPERSONS: *(Alphabetically)*

Prof. Enayat Ezzat
Prof. Mohamed Reda Halawa *(Ain Shams University)*
Prof. Raafat Rashwan *(Zagazig University)*

	SESSION	SPEAKER
10 Min	When not to escalate	**Prof. Yehia Ghanem** *(Alexandria University)*
10 Min	The short cut for early and tight control	**Prof. Mohamed Reda Halawa** *(Ain Shams University)*

16:55 -17:15 Coffee Break

SESSION 27 17:20 - 18:10 | Hall A Cleopatra

MENA SYMPOSIUM

CHAIRPERSONS: *(Alphabetically)*

Prof. Abdel Razak Almadani *(UAE)*
Prof. Dalal Alromaihi *(Bahrain)*
Prof. Hana El Ghanem *(Syria)*
Prof. Inass Shaltout *(Cairo University)*
Prof. Jamal Belkhadir *(Morocco)*
Prof. Mohamed Sandid *(Lebanon)*

	SESSION	SPEAKER
20 Min	Challenges in initiation or intensification of injectable therapy	**Prof. Jamal Belkhadir** *(Morocco)*
10 Min	**Discussion**	

PANELISTS: *(Alphabetically)*

Prof. Bashir Tarazi *(Palestine)*
Prof. Hazim Abdulrazak *(Iraq)*
Prof. Jamal Belkhadir (Morocco)
Prof. Nadima Shegem (Jordan)
Prof. Zayed Atef (Yemen)

	SESSION	SPEAKER
5 Min	Comprehensive Care of Patients with diabetes	**Prof. Mohamed Sandid** *(Lebanon)*
15 Min	**Panel Discussion**	

SESSION 28 18:15 - 19:15 Hall A Cleopatra

DIABETES/LIVER, MAFLD

CHAIRPERSONS: *(Alphabetically)*

Prof. Ali Gaballa *(Cairo University)*
Prof. Bahaa Abbas *(Military Medical Academy)*
Prof. Ashraf Abo Bakr *(Military Medical Academy)*
Prof. Sherif M. Abdel Fattah *(Military Medical Academy)*

MODERATOR:

Prof. Abdel Khalik Hamed *(Military Medical Academy)*

	SESSION	SPEAKER
10 Min	**NAFLD Epidemiology, Pathogenesis and New Nomenclature.**	**Prof. Hosny Salama** *(Cairo University)*
10 Min	**Diagnosis of MAFLD. Present & New Drugs for MAFLD**	**Prof. Mona Amin** *(Cairo University)*
10 Min	**Clinical Impact of MAFLD**	**Prof. Medhat El Sahhar** *(Police Academy)*
10 Min	**Case Presentation in Diabetic MAFLD**	**Prof. Abdel Khalik Hamed** *(Military Medical Academy)*
	19:20 Lunch	

FRIDAY
29 OCTOBER
2021

SESSION 29 10:00 - 11:00 — Hall A Cleopatra

Advances in Diabetes

CHAIRPERSONS: *(Alphabetically)*

Prof. Alia Alaghoury	*(Alexandria University)*	Prof. Iman El Sherif	*(Suez Canal University)*
Prof. Ali Abbasi	*(Alexandria University)*	Prof. Raafat Rashwan	*(Zagazig University)*
Prof. Hussein EL Fishawy	*(Cairo University)*		

	SESSION	SPEAKER
17 Min	Diabetes Management with Control-IQ Advanced Technology	Prof. Hazem Ashmawy *(Zagazig University)*
17 Min	The Complex Play of Genetics in Diabetes: Insights into the Pathogenesis and its Clinical Application	Prof. Nancy Elbarbary *(Ain Shams University)*
17 Min	Renal Protection in Diabetes	Prof. Mick Kumwenda *(UK)*
5 Min	Discussion	

SESSION 30 11:05 - 12:05 — Hall A Cleopatra

Updates in Obesity and Management

CHAIRPERSONS: *(Alphabetically)*

Prof. Alia Alaghoury	*(Alexandria University)*	Prof. Hanaa Taha	*(Cairo University)*
Prof. Ali Abbasi	*(Alexandria University)*	Prof. Iman Kamel	*(National Research Centre)*
Prof. Fahmy Amara	*(Alexandria University)*	Prof. Samir Naim	*(Alexandria University)*
Prof. Hamdoun Lhassani	*(Morocco)*		

	SESSION	SPEAKER
17 Min	Women and Obesity	Prof. Inass Shaltout *(Cairo University)*
17 Min	Cardiovascular Diseases in Obesity	Prof. Amr El Meliegy *(Cairo University)*
17 Min	New Treatments in Diabetes and Obesity"	Prof. Tatjana Milenkovic *(Macedonia)*
5 Min	Discussion	

12:05-12:40
Coffee Break and Friday Prayer

SESSION 31 12:45- 13:55 — Hall A Cleopatra

CHAIRPERSONS: *(Alphabetically)*

Prof. Abdel Majid Chraibi *(Morocco)*
Prof. Ayman El Menoufy
Prof. Iman El Sherif *(Suez Canal University)*
Prof. Mazen Attia *(Cairo University)*
Prof. Samir Helmy Assad *(Alexandria University)*

	SESSION	SPEAKER
20 Min	Diabetes Epidemiology	Prof. Luis Gardette *(Purtugal)*
20 Min	Do Sulfonylureas Have a Role in 2021?"	Prof. Samir Naim *(Alexandria University)*
20 Min	HbA1c: All that Glitters is not Always Gold!	Prof. Magdy Helmy *(Alexandria University)*
10 Min	Discussion	

SESSION 32 14:00 - 15:00 — Hall A Cleopatra

Diabetes in Special Situations

CHAIRPERSONS: *(Alphabetically)*

Prof. Eman Medhat *(Cairo University)*
Prof. Hoda Gouda *(Zagazig University)*
Prof. Magdy Helmy *(Alexandria University)*
Prof. Mazen Attia *(Cairo University)*
Prof. Moghazy Mahgoub *(Ain Shams University)*
Prof. Shabeen Naz Masood *(Pakistan)*

	SESSION	SPEAKER
17 Min	Diabetes and Thyroid	Prof. Farid Fawzy *(Zagazig University)*
17 Min	Diabetes with Pregnancy	Prof. Assem Sief *(Cairo University)*
17 Min	Diabetes and COVID-19	Prof. Aliaa Alaghoury *(Alexandria University)*
6 Min	Discussion	

SESSION 33 15:05 - 15:45 — Hall A Cleopatra

Diabetes Economics & Advances

CHAIRPERSONS: *(Alphabetically)*

Prof. Hoda Gouda *(Zagazig University)*
Prof. Mabaheg Souka *(Alexandria University)*
Prof. Mayada Mousa *(Zagazig University)*
Prof. Mohamed F. Abdel Aziz *(Ain Sham University)*

	SESSION	SPEAKER
17 Min	Cost Effectiveness of Diabetes Therapies	**Prof. Iman El Sherif** *(Suez Canal University)*
17 Min	Perspectives on the Use of Artificial Intelligence in the Retinopathy Screening Programmes	**Prof. Sehnaz Karadeniz** *(Turkey)*
5 Min	Discussion	

SESSION 34 15:50 - 16:30 — Hall A Cleopatra

Advances in Diabetes in Therapy

CHAIRPERSONS: *(Alphabetically)*

Prof. Iman El Sherif *(Suez Canal University)*
Prof. Mazen Attia *(Cairo University)*
Prof. Mohamed Fahmy Abdel Aziz *(Cairo University)*

	SESSION	SPEAKER
17 Min	Technology in Diabetes for Children and Adolescents	**Prof. Banshi Saboo** *(India)*
17 Min	Novel and Future Diabetes Therapies	**Prof. Dario Rahelic** *(Croatia)*
5 Min	Discussion	

SESSION 35 16:40 - 17:20 — Hall A Cleopatra

CHAIRPERSONS: *(Alphabetically)*

Prof. Hazem Ashmawy *(Zagazig University)*
Prof. Iman El Sherif *(Suez Canal University)*
Prof. Sahar Elheiny *(Menia University)*
Dr. Sayed Gad

⏱	SESSION	SPEAKER
17 Min	Novel and Future Diabetes Therapies	Prof. Zaman Shaikh *(Pakistan)*
17 Min	Secondary Diabetes Mellitus How to Recognise and Treat	Prof. Asaad Aldaftar *(Bahrain)*
4 Min	Discussion	

SESSION 36 17:20 – 17:50 — Hall A Cleopatra

PHARMA SYMPOSIA

CHAIRPERSONS: *(Alphabetically)*

Prof. Mayada Mousa *(Zagazig University)*
Prof. Sahar ElHeiny *(Menia University)*
Dr, Sayed Gad

HSO SYMPOSIUM

⏱	SESSION
20 Min	HSO/Marcyrl presentation Gliflozamet

ATCO SYMPOSIUM

⏱
10 Min

⏱	SESSION	SPEAKER
17:55 - 18:10	Closing Remarkes & AASD 2021 Recommendations	
18:15	Lunch	

SESSION 37 10:00 - 10:40 — Hall B Teba

Dyslipidemia, Hypertension and Insulin Resistance

CHAIRPERSONS: *(Alphabetically)*

Prof. Amira Ahmed *(Zagazig University)*
Prof. Mona Yousry *(Cairo University)*
Prof. Rasha Sobh *(Cairo University)*

	SESSION	SPEAKER
15 Min	The Power of Control Hypertension in Diabetics	Prof. Shaymaa AbdelMaboud *(Bahrain)*
20 Min	Dyslipidemia in Diabetes	Prof. George Thompson *(UK)*
5 Min	Discussion	

SESSION 38 10:45 - 11:45 — Hall B Teba

Neuroskeletal Complications in Diabetes

CHAIRPERSONS: *(Alphabetically)*

Prof. Amin Roshdy *(Cairo University)*
Prof. Amira Ahmed *(Zagazig University)*
Prof. Hosny El Fayomy
Prof. Mona Yousry *(Cairo University)*

	SESSION	SPEAKER
17 Min	DPN from Periphery to Central	Prof. Hesham Magd Eldin *(Cairo University)*
17 Min	(PCS) and Diabetes	Prof. Amal Fouad *(Cairo University)*
17 Min	Obese Brain Crosstalk between Obesity and Brain	Prof. Rasha Sobh *(Cairo University)*
5 Min	Discussion	

11:45-12:30 Coffee Break & Friday Prayers

SESSION 39 12:35 - 13:45 | Hall B Teba

Diabetes and liver interrelation

CHAIRPERSONS: *(Alphabetically)*

Prof. **Amr Fatin**	*(Ain Shams University)*
Prof. **Amr Helmy**	*(Menoufya University)*
Prof. **Hossam Zaki**	*(Military Medical Academy)*
Prof. **Magdy El Dahshan**	*(Al Azhar Uniersity)*
Prof. **Omar Hiekal**	*(Military Medical Academy)*

MODERATOR: Prof. Abdel Khalik Hamed *(Military Medical Academy)*

	SESSION	SPEAKER
10 Min	**Diabetes and Liver Cirrhosis**	Prof. **Mona Elamir** *(Cairo University)*
10 Min	**Differentiation of Hepatogenous DM from Primary DM**	Prof. **Mohamed-Naguib Wifi** *(Cairo University)*
10 Min	**Effect of Treatment of Chronic HCV Patients on their Glucose Control**	Prof. **Gamal Esmat** *(Cairo University)*
10 Min	**Infections in Immunocompromized Diabetic Hepatic and may be Mucoromycosis**	Prof. **Hassan Hamdy** *(Cairo University)*
10 Min	**If Transplantation is Required, do you Set a New Target for Control of Sugar?**	Prof. **Mohamed Elbohri** *(Cairo University)*

SESSION 40 13:50 - 14:40 — Hall B Teba

Diabetes CVD and Dyslipidemia

CHAIRPERSONS: *(Alphabetically)*

Prof. **Hala Naguib Hosny** *(Cairo University)*
Prof. **Kebira Benabed** *(Morocco)*
Prof. **Rasha Sobh** *(Cairo University)*

	SESSION	SPEAKER
15 Min	Cardiovascular Trials and Anti-Diabetic Management	Prof. **Nebojša M. Lalić** *(Bosnia)*
15 Min	Updates on the Role of Dyslipidemia in Diabetic Retinopathy	Prof. **Sehnaz Karadeniz** *(Turkey)*
15 Min	Cardiovascular Diseases in Diabetes.	Prof. **Mick Kumwenda** *(UK)*
5 Min	**Discussion**	

SESSION 41 14:45 - 17:00 — Hall B Teba

AASD Championship

4 TEAMS :

Cairo University
Beni Suef University
Suez Canal University
National Diabetes institute

MODERATOR:

Prof. **Mohamed-Naguib Wifi**

ABSTRACTS

The role of circulating soluble fms-like tyrosine kinase-1 in patients with diabetic foot ulcer: A possible mechanism of pathogenesis via a novel link between oxidative stress, inflammation and angiogenesis

Authors: Yasser M Hafez, Tanta University Hospital
Corresponding Author: 1- Sarah Ragab 2- Rasha A. Elkholy

Abstract

Background:

Diabetic foot ulcer (DFU) is one of the most devastating diabetic consequences leading to amputations. Oxidative stress, inflammation, vascular insufficiency and neuropathy have been linked to DFU development. Since soluble fms-like tyrosine kinase-1 (sFlt-1) is one of the anti-angiogenic factors regulating vascular endothelial growth factor (VEGF) biological activity. So, we aimed to evaluate its role in pathogenesis of DFU and its correlation with oxidative stress and inflammatory markers.

Methods:

60 type 2 diabetic patients: 30 without DFU and 30 with DFU in addition to 20 healthy controls were enrolled in the study. sFlt-1 and VEGF mRNA relative gene expressions and levels and sFlt-1/VEGF ratio were assessed. Also, Advanced oxidation protein products (AOPPs), malondialdhyde (MDA), Total thiol and, tumor necrosis factor alpha (TNF-α) levels were measured.

Results:

sFlt-1 expression and level, AOPPs, MDA and TNF-α were significantly higher in diabetic patients as compared with the control group with highest levels in DFU patients. However, there were significant decrease in total thiol level and VEGF expression and level in diabetic patients with DFU.
Conclusion:This study revealed that sFlt-1 is a major player in DFU pathogenesis and may be considered as a novel diagnostic biomarker for early detection of DFU.

Preparation and Evaluation of Novel Anti-Obesity Immunoglobulins for Immunoprophylaxis and Therapy

Authors' Names : Manal Mohamed Elsayed Ahmed, National Research Centre
Corresponding Author: Walid Nazmy, Jakeen Eljakee

Abstract

Obesity is one of the largest and fastest growing public health problems in the world. The pharmacological options for obesity treatment remain quite limited. Recently, one of the potential exciting research areas is the development of innovative therapeutic molecular vaccines and immunoglobulins. Here, we developed novel immunoglobulins against obesity containing anti-ghrelin O-acyltransferase (GOAT) IgY to block the activity of the appetite-stimulating hormone "ghrelin".

Its preliminary pre-clinical evaluation was applied into 3 mice groups, (A) was fed standard pellet chow, (B) was fed a high-fat diet with metabolizable energy contents of 13% kcal from fat and (C) was fed a high-fat diet with metabolizable energy contents of 45% kcal from fat.

Oral immunization with this biologics successfully induced beneficial responses that attenuated body weight gain by decreasing food intake and increasing energy expenditure. Anti-GOAT IgY is a promising approach for the treatment of obesity by oral administration but further studies are still required before entry into clinical trials as its effect on physical activity and visceral adipose tissue.

A high incidence of new onset diabetes among patients With COVID-19 admitted to hospital

Authors' Name : Majid H Alabbood, Consultant Endocrinologist at Alzahraa College of Medicine
Corresponding Author: Wedad Mizher, Essam Alshawy, Zena Albuswalem

Abstract

Background:

This study aims to estimate the incidence of NODM among patients with COVID-19 admitted to hospital.
Methods: A retrospective cross-sectional study conducted from October to December 2020 on 1011 patients. Data were extracted from records of patients admitted to COVID-19 wards and ICU.Patients were diagnosed as having NODM according to the American Diabetes Association (ADA) criteria (1).

Results:

Males represent 58.4% of the participants. Mean age was 55.6 years. Approximately, 1/5 (20.5%) of the participants were managed at ICU. NODM was reported in 26.7% of the patients (44.8% of those who do not have past history of diabetes). Pre-existing diabetes was reported in 40.4%. Accordingly, 679 (67.1%) were having diabetes both known and NODM. Mean plasma glucose for those with diabetes was = 334 mg/dL.Insulin therapy was used in 444 (65.3% of those with diabetes). Mortality rate was 24.3%. Those with NODM were more likely to be admitted to the isolation ward rather than ICU compared to those without (21.3% vs 18.5%, p=0,0005). In contrast, those with pre-existing diabetes were more likely to be admitted to ICU (22.4% vs 19.2%, p=0.0005).
Mortality rate was higher among those with pre-existing diabetes than those with NODM (27.6% vs 21.1%, p=0.0005). Mortality rate among those with diabetes was more than those without (25% vs 22.8%, p=0005).

Conclusion:

A high incidence rate of NODM and prevalence rate of diabetes were reported in this cohort of patients. Quarter of patients admitted to the hospital for moderate-severe COVID-19 died. Future studies which include pre-admission data on glucose profile as well studies on the incidence of NODM among mild-moderate cases of COVID-19 are required.

Evaluation of physicians` approaches for the management of patients with diabetes during Ramadan in Iraq

Authors' Name : Majid H Alabbood, Consultant Endocrinologist at Alzahraa College of Medicine
Corresponding Author: Rafid Alameri, Yasameen Alsaffar

Abstract

Background:

This survey aims to investigate approaches adopted by Iraqi physicians for the management of diabetes during Ramadan.
Methods: A cross-sectional online survey conducted via Google forms from March 20 through March 27, 2021. The participants were specialist doctors directly involved in management of people with diabetes mellitus. Repeat submissions from the same link were automatically blocked by the survey server. A total of 140 responses collected in this study.

Results:

Majority of the participants were family physicians followed by internal medicine physicians and endocrinologists in the following rates 29.2 %, 27.1 % and 16.4 % respectively. Among the respondents, 94.3% reported giving advice to their patients regarding Ramadan fasting; 84.3% of this advice was based on several factors (Table 1). Those who do not follow a specific guideline in their provision of care and depend on their experience represent 53%. Of them, family physicians were the predominant (70.2%). Pre-Ramadan education is provided by 75% of the participants. Minority (14.3%) allow patients with type 1 diabetes to fast Ramadan and 32.1% allow those with T2D on insulin to fast. Recent DKA and recent severe hypoglycemia were the main causes for not allowing people to fast Ramadan, 79.3% and 74.3% respectively (Table 2). Regarding treatment modification during fasting, 56.4 % of physicians change the frequency of administration. Lastly, 67.8 % scored 7/10 or above in the questions to test the familiarity of physicians with the established international guidelines.

Conclusion:

This survey highlights the importance of medical education for doctors and the need for structural education programs directed to the family physicians, internists, and other treating physician regarding the current practical guidelines. Health care providers need to be familiar with current diabetes and Ramadan fasting guidelines.

A study on diabetes in Ramadan in Iraq

Authors' Name : Majid H Alabbood, Consultant Endocrinologist at Alzahraa College of Medicine
Corresponding Author: Wedad Mizher, Mustafa Alsudani, Hayat Almousawi

Abstract

Background:

This study aims to examine the effect of Ramadan fasting on people with diabetes and to describe the behavior of people with diabetes in Ramadan in Iraq.

Methods:

This was a physician administered face to face questionnaire conducted shortly after Ramadan 2018. Age, gender, diabetes type and duration, drug history, comorbidities and last HbA1c were recorded. Duration of Ramadan fasting, hypoglycemia and hyperglycemia events and pre-Ramadan education were assessed. A total of 543 responses were collected. Results: Females represent 58.1% of the participants. Mean age was 51 years with mean duration of diabetes of 8.3 years. Majority (90.5%) of the participants had type 2 diabetes. The years. The mean last recorded HbA1c was 9.3%. Majority (75.5%) were on metformin alone or in combination with other medications. While 51.9%, 12.8% and 8.6% were on insulin, sulphoylurea and no medications respectively. Of the participants, 56.4% have diabetes related complications. Only 17.6% received pre-Ramadan education. Majority of the patients (73.8%) fasted Ramadan. Of these, 80.7% fasted the whole month. Only, 3.6% of those who fasted experienced severe hypoglycemia. Only 19.7% were checking their blood sugar daily during Ramadan fasting; of them, one patient was using the flush glucose monitor.

Conclusion:

A high proportion of Iraqi patients with type 2 diabetes fast during Ramadan with the majority fast the whole month. However, the level of pre-Ramadan education and glucose monitoring was inadequate. Many patients on insulin fast Ramadan relatively safely without modifying the dose of their treatment or regimen. Minority of patients developed severe hypoglycemia. More programs and campaigns to educate patients with diabetes on the importance of pre-Ramadan counselling is needed.

Role of MicroRNA as a marker in detection of Diabetic Nephropathy in Type 2 Diabetic Egyptian Patients

Authors' Name: Elsayed Ghonamy, Lecturer at Faculty of Medicine Ain Shams University

Abstract

Background:

Diabetic kidney disease (DKD) represents the major cause of chronic kidney disease (CKD). New biomarkers for early diagnosis of DKD is of interest. Our objective is to elucidate the significance of microRNA-192 and Neutrophil Gelatinase-Associated Lipocalin (NGAL) as an early predictors of diabetic nephropathy in comparison with albuminuria in type2 Diabetic patients.

Patients and methods:

A number of 45 persons on 3 groups, group 1: 15 healthy persons with no diabetes mellitus. group 2: 15 patients diagnosed type 2 diabetes mellitus without albuminuria. group 3: 15 patients diagnosed type 2 diabetes mellitus with albuminuria. Estimation of serum MicroRNA, NGAL ,Urine albumin /creatinine ratio, Serum creatinine ,urea, Fasting blood glucose(FBG), 2 hour post prandial blood glucose and HbA1c.

Results:

The study showed that the serum miR-192&NGAL levels were significantly higher in patients diagnosed type 2 diabetes mellitus with albuminuria in comparison with patients diagnosed type 2 diabetes mellitus without albuminuria. There was significant positive correlation between MicroRNA-192& NGAL and urine Albumin/Creatinine ratio.

Conclusion:

Serum NGAL and micro RNA-192 may serve as tools to follow up the development and progression of diabetic kidney disease.

Role of MicroRNA as a marker in detection of Diabetic Nephropathy in Type 2 Diabetic Egyptian Patients

Authors' Name: Elsayed Ghonamy, Lecturer at Faculty of Medicine Ain Shams University

Abstract

Background:

Diabetic kidney disease (DKD) represents the major cause of chronic kidney disease (CKD). New biomarkers for early diagnosis of DKD is of interest. Our objective is to elucidate the significance of microRNA-192 and Neutrophil Gelatinase-Associated Lipocalin (NGAL) as an early predictors of diabetic nephropathy in comparison with albuminuria in type2 Diabetic patients.

Patients and methods:

A number of 45 persons on 3 groups, group 1: 15 healthy persons with no diabetes mellitus. group 2: 15 patients diagnosed type 2 diabetes mellitus without albuminuria. group 3: 15 patients diagnosed type 2 diabetes mellitus with albuminuria. Estimation of serum MicroRNA, NGAL ,Urine albumin /creatinine ratio, Serum creatinine ,urea, Fasting blood glucose(FBG), 2 hour post prandial blood glucose and HbA1c.

Results:

The study showed that the serum miR-192&NGAL levels were significantly higher in patients diagnosed type 2 diabetes mellitus with albuminuria in comparison with patients diagnosed type 2 diabetes mellitus without albuminuria. There was significant positive correlation between MicroRNA-192& NGAL and urine Albumin/Creatinine ratio.

Conclusion:

Serum NGAL and micro RNA-192 may serve as tools to follow up the development and progression of diabetic kidney disease.

Role of Resistin, IL-6 and NH2-Terminal Portion-ProBNP in Cardiac Pathogenesis in Patients with Diabetes Mellitus

Authors' Name: Mohamed Abdel-Samiee, Hepatology and Gastroenterology, National Liver Institute- Samar Ebrahim Ghanem[1],

Corresponding Authors: Mohamed Hamdy Torky[3], Ahmed Gaafar[4], Somia Mokabel Mohamed[5], Ghada Mohamed Mohamed Salah Eldin[5], Samah Mohammed Awad[6], Karema A. Diab[7], Dalia M ELsabaawy[8], Sania Ali Yehia[9], Hany Abdelbary Abdelaziz Elbasyouni[10] Amr A. Elshormilisy[11]

Abstract

Epidemiological and genetic studies have recorded the association between proinflammatory cytokines and the development of insulin resistance, diabetes, and cardiovascular disease. The role of interleukin 6 (IL-6), NH2-terminal portion pro-brain natriuretic peptide (NT-proBNP) and resistin in the pathogenesis of heart disease in type 2 diabetes mellitus (T2DM) is still a matter of controversy.

Aims:

We aimed to evaluate the role of these biomarkers in the development of left ventricular systolic dysfunction and prediction of left ventricular hypertrophy and systolic dysfunction in T2DM.

Methods:

This case-control study included 150 participants. Group 1a included 46 patients with DM and echocardiographic evidence of abnormal systolic function; group 1b included 54 patients with normal echocardiogenic study; and group 2 included 50 controls. Routine laboratory investigations were measured after consent at NLI. Conventional echocardiography was done with special concern on the assessment of left ventricular systolic function (ejection fraction). Results There was a significant increase in the level of resistin, NT-proBNP and IL-6 in group 1a patients compared with group 1b and in healthy controls. Echocardiographic parameters showed a significant increase in left ventricular mass index, left ventricle posterior wall thickness, interventricular septum, and left ventricle mass in group 1a compared with group 1b and the control group. The increased left ventricular mass index was associated with higher levels of IL-6, NT-proBNP and resistin.

Conclusions:

Proinflammatory cytokines had a relation with left ventricular systolic dysfunction and hypertrophy and can be used as non-invasive markers for left ventricular remodeling detection and systolic dysfunction in patients with T2DM.

Obesity and Waist Circumference are Possible Risk Factors for Thyroid Cancer: Correlation with Different Ultrasonography criteria

Authors' Name: Marwa Sayed Eissa, Assistant professor, Cairo University
Corresponding Authors: 1- Mona Sayed abdellatif, 2- Ula M AL jarhi, 3- Yasmin F Elesawy, 4- Sabry Shaarawy

Abstract

Background:

Obesity has an important role in the pathogenesis of cancer; however, there are no clear mechanisms explaining the association between obesity and risk of thyroid cancer (TC).

Methods:

It is a cross-sectional study including 184 patients with benign thyroid nodules (BN) and 19 patients with TC. Body mass index (BMI), waist circumference (WC), hip circumference (HC), waist/hip (W/H) ratio were assessed and correlated to relevant clinico-pathological features of the patients, different ultra-sonographic (U/S) criteria and risk of malignancy.

Results:

There was a significant increase in BMI, WC and W/H ratio in TC patients compared to BN group (P=0.001, 0.011 and 0.003). Increased BMI, WC and HC were associated significantly with solid nodules (P<0.05).
WC increased in hypoechoic (103.1 ±15.4cm) and heterogeneous (103.8±16.7cm) nodules, compared to isoechoic (97.3±15.5cm) and hyperechoic (96.1±10cm) nodules (P=0.046). It also increased with lymph nodes enlargement (P=0.04).

There was a significant association between WC and TIRADS classification (P=0.032), as it increased with TR4b (118.5 ± 12.9 cm) and TR5 (117.3 ± 13.9 cm) compared to TR2 (114.1 ± 15.7 cm, P=0.025 and 0.008, respectively). WC is an independent predictor for TC [OR: 1.092, CI: 1.020–1.170, P=0.012]. It achieved sensitivity, specificity and AUC (71.4%, 68.7% and 0.750; respectively), at a cutoff value of 108.5 cm (P=0.003), and when combined with BMI at a cutoff value of 32.59 (77.8% and 68.4%, respectively, AUC: 0.780, P<0.001).

Conclusions:

Central adiposity is strongly associated with the risk of TC. WC is more superior to BMI when correlated with TIRADS classification and also is an independent predictor for TC.

Correlation between serum neopterin level and carotid artery intima- media thickness in type 2 diabetic patients.

Authors' Names: Mohamed Abdelhamid Mohamed Mahmoud, Internist at Al Fayoum General Hospital
Corresponding Authors: 1- PROF.DR. Mohamed Abdelhady Mashahet, 2- DR. Sally Nabil Abouelseoud, 3- DR. Othman Mostafa Ahmed Zaki

Abstract

Background:

Atherosclerosis is currently viewed as an immune-mediate inflammatory disease of the arterial wall, macrophages play an important role in atherogenesis.Inflammatory mechanisms with atherosclerotic plaque formation can be triggered,maintained and enhanced by multiple factors such as activated macrophages that induce synthesis of neopterin.The aim of the study is to evaluate the association between serum neopterin level and carotid atherosclerosis in type 2 diabetic patient and to highlight the role of inflammation in atherosclerosis and atherosclerotic cardiovascular disease.

Patients and methods:

This is a prospective study include (96) subjects, they were divided into three groups: group A (32)
T2DM patients without cardiovascular complications, group B (32) T2DM patients with cardiovascular complications and group C (32) healthy control subjects.All Subjects in this study were subjected to full clinical examination and laboratory investigations as FBS,2hrsPP,HBA1c,lipid profile. measurement of serum neopterin level , hs-CRP and carotid duplex to measure carotid artery intima-media thickness.

Results:

Serum neopterin shows higher values in group B patients with a statistical positive correlation between serum neopterin and hs-CRP in group B p-values 0.041,also serum neopterin shows higher values in patients with echolucent plaques in group B. A statistical positive correlation between serum neopterin and CA-IMT.was found P.value (A+B), also, A statistical positive correlation between serum neopterin and hs-CRP. was found

Conclusions:

Serum neopterin is a marker of both macrophage activation and redox system activation and could be used as a potential biomarker in risk stratification while assessing and managing atherosclerotic cardiovascular diseases.

Influence of Prediabetes on Hospital Outcome after Coronary Artery Bypass Grafting

Authors' Name: Yasser Shaban Mubarak, Minia University Hospital
Corresponding Authors: 1- Yasser Ali, 2- Mohamed Amr

Abstract

Background:

Prediabetes is a precursor stage of Diabetes Mellitus (DM) affecting progress of coronary atherosclerosis. Objective: To evaluate the association of prediabetes with adverse outcome after isolated coronary Artery Bypass Grafting (CABG).

Patients and methods:

This retrospective study of 3655 patients underwent CABG, identified 2150 non-diabetic patients after re-evaluation of glucose tests and HbA1c. Prediabetes was defined according to criteria of American Diabetic Association (ADA). Non-diabetic patients were divided into prediabetes (n=1068) and control (n=1082) groups. The primary outcome measures were early mortality and Major Cardiovascular And Cerebral Adverse Events (MACCE).

Results:

Preoperative, operative and postoperative variables were similar between both groups. There was no significant association between prediabetes and postoperative adverse outcome. Receiver Operating Characteristic (ROC) plot demonstrates that HbA1c had a good accuracy to predict all-cause mortality, cardiac mortality, and MACCE. On multivariate logistic regression, the independent preoperative predictors of early mortality and MACCE in prediabetic patients were: age >70 years, dyslipidemia, and hypertension.

Conclusions:

Prediabetes does not negatively affect early outcome after CABG, however coexistence of older age, dyslipidemia or hypertension with prediabetes could increase the odds of early mortality and MACCE. Preoperative screening for prediabetes using HbA1c, correction of the associated modifiable cardiovascular risk factors, and further studies are recommended.

Influence of Prediabetes on Hospital Outcome after Coronary Artery Bypass Grafting

Authors' Name: Yasser Shaban Mubarak, Minia University Hospital
Corresponding Authors: 1- Yasser Ali, 2- Mohamed Amr

Abstract

Background:

Prediabetes is a precursor stage of Diabetes Mellitus (DM) affecting progress of coronary atherosclerosis. Objective: To evaluate the association of prediabetes with adverse outcome after isolated coronary Artery Bypass Grafting (CABG).

Patients and methods:

This retrospective study of 3655 patients underwent CABG, identified 2150 non-diabetic patients after re-evaluation of glucose tests and HbA1c. Prediabetes was defined according to criteria of American Diabetic Association (ADA). Non-diabetic patients were divided into prediabetes (n=1068) and control (n=1082) groups. The primary outcome measures were early mortality and Major Cardiovascular And Cerebral Adverse Events (MACCE).

Results:

Preoperative, operative and postoperative variables were similar between both groups. There was no significant association between prediabetes and postoperative adverse outcome. Receiver Operating Characteristic (ROC) plot demonstrates that HbA1c had a good accuracy to predict all-cause mortality, cardiac mortality, and MACCE. On multivariate logistic regression, the independent preoperative predictors of early mortality and MACCE in prediabetic patients were: age >70 years, dyslipidemia, and hypertension.

Conclusions:

Prediabetes does not negatively affect early outcome after CABG, however coexistence of older age, dyslipidemia or hypertension with prediabetes could increase the odds of early mortality and MACCE. Preoperative screening for prediabetes using HbA1c, correction of the associated modifiable cardiovascular risk factors, and further studies are recommended.

Biological effects of human amniotic membrane products on diabetic foot ulcers: A Systematic Review and Meta-analysis

Authors' Name: Mohamed Ibrahim Gbreel, October 6 University
Corresponding Authors: 1- Yasmine Adel Mohammed, 2- Hossam Khaled Farouk, 3- Abdelrahman Mahmoud Ali, 4- Ali Ashraf Salah Ahmed, 5- Mohamed Mahmoud Abd-ElGawad

Abstract

Background:

Diabetic foot ulcer (DFU) is one of the most serious diabetic complications. DFU is an open wound that usually occurs in the foot sole due to poor blood glucose control, peripheral neuropathy, and poor circulation. The human amniotic allograft membrane is a biologic wound dressing derived from the amniotic membrane. It contains amino acids, nutrients, cytokines, and growth factors that make the growth process easier.

Objective:

To compare dehydrated human amnion and chorion allograft (DHACA) with the standard of wound care (SOC) and the SOC alone.

Methods:

We searched for randomized clinical trials (RCTs) on PubMed, Scopus, Cochrane, Web of Science, and GHLtill April 2021 using relevant keywords. All search results were screened for eligibility. We extracted the data from the included trials and pooled them as mean difference (MD) with 95% confidence interval (CI) or risk ratio (RR) with 95% CI, using Review Manager software (ver. 5.4).

Results:

The pooled effect estimate from 11 RCTs showed that DHACA was superior to SOC regarding the complete wound healing in both 6th and 12th week (RR=3.78; 95%:CI [2.51, 5.70]; P<0.00001); (RR=2.06, 95% CI:[1.71, 2.48], P<0.00001) respectively. Also, the analysis favored the DHACA regarding the 12th-week healing (RR=-12.07, 95% CI:[-19.23, -4.91], P=0.001). The wound size reduction was better with DHACA than SOC alone (RR=0.42, 95% CI:[-0,53, 1.37], P=0.02).

Conclusions:

Using DHACA with SOC is safer and more effective than using SOC alone for DFU patients.

Sex steroids in association with PAD in elderly men

Authors' Names Affiliation: Dr Ahmed Adel Mohamed, Suez Canal Authority
Corresponding Author Affiliation: 1- Prof. Dr. Olfat ahmmed Fawzym, 2- Prof. Dr. Mervat al shahat al wakeel

Abstract

Introduction:

Peripheral Arterial Disease (PAD) refers to atherosclerotic occlusive disease of the lower extremities. Serum testosterone decreases with aging, while sex hormone-binding globulin (SHBG) is reported to increase with age. Data associating sex steroids with PAD are conflicting. Aim of the work: to investigate if there is an association between serum levels of Testosterone (T), Estradiol (E2), SHBG and ankle brachial index (ABI) as a measure of lower extremity PAD in elderly men. Subjects and methods: A total of 80 elderly men > 65 years constituted the study subjects. Forty patients had PAD and forty patients did not have PAD. Ankle Brachial Index (ABI) was done for all subjects using a hand-held Doppler to confirm the diagnosis of PAD. In addition to metabolic panel, total T and free T (TT and fT), E2 and SHBG were measured. Results: TT was lower in PAD group (group 1) when compared to non-PAD group (group 2). Levels of TT were lower in patients with PAD and DM (group 1a) when compared to patients with PAD only (group 1b). Moreover, SHBG levels showed higher values in PAD with DM group (1a) compared to PAD only group (1b). In the studied population, there were positive correlation between ABI and Body weight (BW), height, body mass index (BMI) and TT. Negative correlation was found between ABI and diastolic blood pressure (DBP) and triglycerides (TGs). Linear regression analysis revealed that BMI is the strongest predictor for ABI followed by TGs, height, BW and DBP in the studied population, while there was insignificant association regarding TT. Conclusions: Lower T levels, but not E2, were associated with PAD in older men. TGs level was confirmed to be a determinant risk factor for PAD. Keywords: PAD, Aging, Testosterone, SHBG, Estradiol, ABI, Triglycerides.

Prevalence and risk factors of peripheral neuropathy in type 2 diabetic patients at Benghazi Diabetic Centre

Authors' Name: Mona Adeeb Khalil 1, Adela.H. Elamami 2

Abstract

Introduction:

Diabetes is a major endocrine disease involving the world, and leading to a lot of complications, the prevalence of these complications is increasing because the prevalence of diabetes is increasing worldwide. One of the complications of diabetes is peripheral neuropathy which is involved in our study.

Objective:

The aim of our study was to:
1) Estimate the prevalence of peripheral neuropathy in type 2 diabetic patients in Benghazi.
2) Identify the risk factors associated with the development of peripheral neuropathy in type 2 diabetic patients.

Methods:

A cross sectional study conducted on 201 type 2 diabetic patients attending OPD at Benghazi diabetic center in the period from march 2017 through September 2018 ,the sample taken from both sex ,the age was > 18 years , Michigan neuropathy screening instrument (MNSI) was used to assess diabetic peripheral neuropathy (composed of 15 questionnaire ,and examination of foots ,the score of >2 is considered to have peripheral neuropathy ,and the data collected were (age , gender , duration of diabetes , HbA1C ,lipid profile , presence of chronic illness , BMI , BP , presence of retinopathy , presence of microalbuminuria ,smoking history , alcohol intake)

Results:

Out of 201 diabetic patient who included in the study, 108 patients (53.7 %) were males and 93 patients (46.3 %) were females , the mean age was (59.04 ± 11.36) years , the mean duration of diabetes was (9.8 ± 8.2) years .The prevalence of Diabetic peripheral neuropathy(DPN) was (41.8 %) , the prevalence of DPN was nearly similar in females and males (41.9 % vs 41.7 %).The risk factors for DPN was old age ,long duration of DM ,smoking , high systolic BP ,high diastolic BP , high total cholesterol , high LDL , high TG , low HDL , presence of retinopathy and micro albuminuria.
There was significant higher prevalence of DPN among patients with HbA1c >7.

Conclusions:

The high prevalence of DPN in type 2 diabetic patients are the cause of concern and must need early screening for PN and it is risk factors, to prevent or delay the development of PN in diabetic patients.

Key words: Outpatient department (OPD) , MNSI Michigan neuropathy screening instrument , ,DPN diabetic peripheral neuropathy , PN peripheral neuropathy.

How to manage gestational diabetes and hashimoto thyroiditis in a woman

Author: Anila Rrupulli, MD
Corresponding Author Affiliation: Brunilda Mehilli

Abstract

Introduction:

Gestational diabetes is defined as any degree of carbohydrate intolerance that is first diagnosed during pregnancy. The prevalence of GDM ranges between 1% and 14% , and it is most frequent in women aged ≥35 years in the second trimester of pregnancy. In a minority (<10%) of patients, the need for insulin therapy continues after delivery.. Recent studies have reported increased incidence of thyroid autoimmunity in type 2 diabetes thus implying that diabetes can trigger the onset of thyroid autoimmunity. Moreover, little is known about thyroid autoimmunity in post-GDM patients, who usually return to normal glucose control after delivery. In our opinion, GDM offers a good opportunity to study if diabetes and hyperglycemia might predispose to thyroid autoimmunity.Case study.One woman has done 3 miscarriges .She has poor glycemic control and hashimoto thyroidits.She is pregnant of 3 weeks.She is consulting to endocrinologist.She is treated with insulinoterapia ,diet and levothyroxine and selenium.Every three months she has done the check up of glycemia cholesterol,trigliceridet,Tsh,Antitpo,and HbA1c.Every three months we see that we have e good control of fasting glycemia not more the 120 mg\dl ,HbA1c not more than 6.8% and normal Tsh under the therapy with levothyroxine. After 9 months we have a good control of glycemia. The baby development is very good in weight and no abnormality. The delivery is successfull. So if we can have e good control of fasting glycemia and HbA1c during the pregnancy we can have a successfully delivery. Poor control develops miscarriage.

661-P: Reduced Glycemic Variability with Once-Weekly Semaglutide vs. Active Comparators in Post-hoc Analysis of the SUSTAIN Program


1- Richard E. Pratley
2- Vanita R. Aroda
3- Charlotte Hindsberger
4- Yasemin Kose
5- Margit Kaltoft and
6- Esteban Jodar

Abstract

High glycemic variability (GV) is independently associated with adverse clinical outcomes such as micro-/macrovascular complications. As glucose-dependent action of once-weekly (OW) semaglutide may translate to reduced GV, we compared within-day GV of OW semaglutide vs. active comparators in people with type 2 diabetes (T2D).

This post hoc analysis was based on individual subject data in the full analysis set (n=5,680) from the on-treatment without rescue medication period in SUSTAIN 2-4, 7, 8 and 10. GV was assessed as change from baseline to end of treatment in standard deviation (SD) of the self-measured blood glucose (SMBG) over the day, if measured ≥6 times. Multiple imputation was used for missing SD values.

The average baseline SD of the SMBGs was 40.1-45.7 mg/dL across all treatment arms in the trials. Significantly larger reductions in SD of SMBGs from baseline to end of treatment were observed with semaglutide 0.5 mg (estimated treatment difference range -3.23 to -3.94 mg/dL) and 1.0 mg (-4.09 to -7.35 mg/dL), vs. comparators (all comparisons $p<0.01$; Figure A). Changes in SD of SMBGs were closely aligned with changes in HbA1c from baseline (Figure B).



In summary, the reduction of within-day GV from baseline was significantly greater with OW semaglutide vs. all active comparators, supporting improvement in clinically relevant outcomes with semaglutide treatment in those with T2D.

Disclosure R. E. Pratley:

661-P: Reduced Glycemic Variability with Once-Weekly Semaglutide vs. Active Comparators in Post-hoc Analysis of the SUSTAIN Program

1- Richard E. Pratley
2- Vanita R. Aroda
3- Charlotte Hindsberger
4- Yasemin Kose
5- Margit Kaltoft and
6- Esteban Jodar

Abstract

Disclosure R. E. Pratley:

Other Relationship; Self; Hanmi Pharmaceutical, Merck Sharp & Dohme Corp., Metavention, Monster Energy Company, Inc., Novo Nordisk, Pfizer Inc., Poxel SA, Sanofi, Scohia Pharma Inc., Sun Pharmaceutical Industries Ltd. V. R. Aroda: Consultant; Self; Applied Therapeutics, Duke, Novo Nordisk, Pfizer Inc., Sanofi, Employee; Spouse/Partner; Janssen, Merck, Research Support; Self; Applied Therapeutics, Eli Lilly and Company, Fractyl, Medpace, Medpace, Novo Nordisk, Premier, Sanofi, Stock/Shareholder; Spouse/Partner; Janssen, Merck. C. Hindsberger: Consultant; Self; Novo Nordisk A/S, Stock/Shareholder; Self; Novo Nordisk A/S, Stock/Shareholder; Spouse/Partner; Novo Nordisk A/S. Y. Kose: Employee; Self; Novo Nordisk A/S. M. Kaltoft: Employee; Self; Novo Nordisk A/S, Stock/Shareholder; Self; Novo Nordisk A/S. E. Jodar: Other Relationship; Self; AstraZeneca, Lilly Diabetes, Mundipharma International, Novo Nordisk, Speaker's Bureau; Self; Boehringer Ingelheim International GmbH.

Funding Novo Nordisk A/S

• © 2021 by the American Diabetes Association
http://www.diabetesjournals.org/content/license
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.

FOR HEALTH CARE PROFESSIONALS ONLY


SOLIQUA™

insulin glargine (100 U/mL) & lixisenatide solution for subcutaneous injection in a prefilled pen (SoloStar)


NOW AVAILABLE IN EGYPT

SOLIQUA™ 30-60

100 units/ml + 33 mcg/ml







SOLIQUA™ 10-40

100 units/ml + 50 mcg/ml

MAT-EG-2101067 8/2021 V 1.0

SANOFI

© 2017. SAGLB.LALI.17.03.0214. March 2017

For further information please contact: SANOFI Egypt
3, EL Massaneh St., Zeitoun, Cairo, Egypt, P.O. BOX: 1486
Tel.: +202 22860000-22860060 Fax: + 202 22860107-22860112


Xultophy®

insulin degludec/liraglutide
[rDNA origin] injection

COMING SOON




MSD
INVENTING FOR LIFE
SMART
MECHANISM
Once-daily
Januvia™
(sitagliptin, MSD)
Janumet™
(sitagliptin/metformin, MSD)


ابدأ بدري
Galvus Met
VERIFY
Galvus Met
Galvus
NOVARTIS

LIPANTHYL® 145mg
FENOFIBRATE
NANOCRYSTAL®
TECHNOLOGY

AVAILABLE NOW



All Prescribing Information are available on request
Abbott Egypt
90th St., Plot 76, First Sector City Center, Fifth Settlement New Cairo, Egypt.
Tel: (202) 26145800 Fax: (202) 26145892
For any adverse events, please email your report to: PV.Egypt@abbott.com
The Abbott symbol and wordmark are registered trademarks of Abbott Laboratories. All rights reserved.

Abbott

Using SYNJARDY cardiovascular protection also available for type 2 diabetic patients on metformin*[1]

SYNJARDY combines the CV death risk reduction of JARDIANCE in a single pill with metformin*[5]

Empagliflozin provided

38%

REDUCTION

RRR in CV death[#2]

SYNJARDY provides up to

4.57%[3]

REDUCTION

in HbA_{1c}[3]

Synjardy®
(empagliflozin/
metformin HCl)

MOH approval code : 0045092/0300310210 | Invalidation date : 23/3/2024 | MLR code : PC-EG-100606

Al Esraa Pharmaceutical Optima

has the pleasure to announce the availability of new strengths of Sugarlo Plus for managing **Type II Diabetes Mellitus...**

NOW! AVAILABLE



Sugarlo
Vildagliptin 50 mg
Tablets

Sugarlo Plus
Film Coated Tablets
Vildagliptin
Metformin HCl
50/500 50/850 50/1000

ALESRAA

MAKE YOUR MISSION POSSIBLE




DIAMICRON® MR 60
Gliclazide
Scored Tablets

YOUR TRUSTED PARTNER

2010 0018 WA. This document is intended for Servier representatives only.

Dapaveldactin/Plus®

Dapagliflozin	5mg	Dapagliflozin / Metformin HCl	5/850mg
Dapagliflozin	10mg	Dapagliflozin / Metformin HCl	5/1000mg



BEYOND GLYCEMIC CONTROL

LIPTIS Pharmaceuticals

Duloxeprin

For Neuropathic Pain







Approved for most types of neuropathic pain

No dose adjustment in elderly & renal patient

Once Daily



is recommended 1st line analgesic for neuropathic pain by

NICE 2019 National Institute for Health and care Excellence	EJP 2016 European Journal of Pain	2014 THE CANADIAN PAIN SOCIETY	American 2019 Diabetes Association

UTOPIA
THE LIFE YOU DESERVE

THANKS TO
AASD 2021 PARTNERS

















































